{"gene":"ABCG2","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":1998,"finding":"ABCG2 (BCRP) was identified as a novel 655-amino acid ABC half-transporter overexpressed in multidrug-resistant MCF-7/AdrVp breast cancer cells; enforced BCRP expression conferred resistance to mitoxantrone, doxorubicin, and daunorubicin, reduced daunorubicin accumulation, and caused ATP-dependent enhancement of rhodamine 123 efflux, establishing ABCG2 as a functional xenobiotic efflux transporter.","method":"cDNA cloning, transfection/overexpression, drug accumulation/efflux assays, RNA fingerprinting","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — original functional reconstitution with multiple orthogonal assays; foundational discovery paper with >1700 citations","pmids":["9861027"],"is_preprint":false},{"year":1998,"finding":"ABCG2 (ABCP) was independently cloned as a human placenta-specific ABC transporter; the predicted protein has a single N-terminal ATP-binding domain and a single C-terminal transmembrane domain (half-transporter architecture), closely related to Drosophila white and yeast ADP1, and maps to chromosome 4q22.","method":"cDNA cloning, sequence analysis, chromosomal mapping, Northern blot","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1 — original molecular characterization; foundational paper with >670 citations","pmids":["9850061"],"is_preprint":false},{"year":1999,"finding":"MXR/BCRP/ABCG2 was independently cloned from mitoxantrone-resistant cells and shown to have homology to the Drosophila white gene; overexpression correlated with resistance to topotecan, SN-38, and mitoxantrone, and pharmacodynamic analysis showed that 70% of the intracellular topotecan pool was effluxed within 30 seconds in overexpressing cells.","method":"Differential hybridization, Northern blot, drug efflux kinetics, partial revertant correlation","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods across multiple cell lines; replicated across labs","pmids":["10493507","9892175"],"is_preprint":false},{"year":2001,"finding":"Amino acid 482 in ABCG2 is a critical determinant of substrate specificity: wild-type arginine at position 482 (R482) transports mitoxantrone but not rhodamine 123 or doxorubicin, whereas acquired mutations R482T or R482G broaden the substrate profile to include rhodamine 123 and anthracyclines, as confirmed by vaccinia virus expression system.","method":"Gene sequencing, vaccinia virus expression, drug efflux and cytotoxicity assays, mutagenesis","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1-2 — site-directed comparison with reconstitution in multiple systems; replicated across labs","pmids":["11559526"],"is_preprint":false},{"year":2001,"finding":"Bcrp1/ABCG2 expression is a conserved molecular determinant of the hematopoietic 'side population' (SP) stem cell phenotype; enforced ABCG2 expression directly conferred the SP phenotype to bone marrow cells and caused reduced maturing progeny both in vitro and in transplantation assays, while Bcrp1 mRNA was sharply downregulated upon differentiation.","method":"Retroviral transduction, flow cytometry (Hoechst 33342 exclusion), transplantation assay, RT-PCR","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 — loss-of-function and gain-of-function with defined cellular phenotype, in vivo transplantation; >1800 citations","pmids":["11533706"],"is_preprint":false},{"year":2001,"finding":"ABCG2 (MXR) transports mitoxantrone and prazosin (BODIPY-prazosin) but not rhodamine 123 in wild-type-expressing cells; fumitremorgin C (FTC) at 1 µM causes half-maximal inhibition of ABCG2-associated ATPase activity, establishing that ABCG2 is an ATPase whose hydrolytic activity is coupled to substrate transport.","method":"Flow cytometry efflux assay, ATPase activity assay, Northern blot","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1-2 — direct ATPase assay combined with functional transport assay","pmids":["11406094"],"is_preprint":false},{"year":2001,"finding":"ABCG2 is expressed in the SP of hematopoietic stem cells and directly mediates Hoechst 33342 efflux; MCF-7 cells retrovirally transduced with ABCG2 showed lower Hoechst 33342 uptake equivalent to drug-selected resistant cells, establishing Hoechst 33342 as an ABCG2 substrate.","method":"Retroviral transduction, flow cytometry, Hoechst 33342 transport assay","journal":"Clinical cancer research","confidence":"High","confidence_rationale":"Tier 2 — gain-of-function with defined substrate transport phenotype, replicated","pmids":["11801536"],"is_preprint":false},{"year":2001,"finding":"Subcellular localization of BCRP/ABCG2 in normal human tissues was mapped by immunohistochemistry: BCRP localizes prominently to the apical membrane of placental syncytiotrophoblasts, the apical surface of small intestine and colon epithelium, the liver canalicular membrane, and venous/capillary endothelium (but not arterial endothelium); differential glycosylation was observed between drug-selected cell lines.","method":"Immunohistochemistry with monoclonal antibodies BXP-21 and BXP-34, immunoprecipitation, Western blot, RT-PCR","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — direct localization experiment with two independent antibodies across multiple human tissues; >900 citations","pmids":["11309308"],"is_preprint":false},{"year":2002,"finding":"In Abcg2 knockout mice, Bcrp1 is required to protect against the dietary phototoxin pheophorbide a (a chlorophyll catabolite) and against protoporphyria: knockout mice developed severe phototoxic skin lesions upon light exposure and showed 10-fold elevated erythrocyte protoporphyrin IX; bone marrow transplant from wild-type mice cured the protoporphyria, establishing that erythroid ABCG2 controls porphyrin levels.","method":"Knockout mouse model, dietary challenge, bone marrow transplantation, erythrocyte porphyrin measurement","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — in vivo knockout + rescue with bone marrow transplantation; >600 citations","pmids":["12429862"],"is_preprint":false},{"year":2002,"finding":"The Q141K (C421A) SNP in ABCG2 results in markedly decreased protein expression (similar mRNA but low protein) and low-level drug resistance in transfected cells; in a Japanese population, heterozygous and homozygous carriers express less BCRP protein, indicating reduced efflux capacity.","method":"Transfection, Western blot, drug resistance assay, population genotyping","journal":"Molecular cancer therapeutics","confidence":"High","confidence_rationale":"Tier 2 — in vitro functional SNP analysis with protein expression measurement, replicated","pmids":["12479221"],"is_preprint":false},{"year":2003,"finding":"Wild-type ABCG2 (Arg482) transports methotrexate (MTX) and its polyglutamate forms (MTX-Glu2, MTX-Glu3) in an ATP-dependent, osmotically sensitive manner as shown by inside-out membrane vesicle transport assays; the mutant Gly482 form does not transport MTX, demonstrating that position 482 also governs MTX transport specificity.","method":"Inside-out membrane vesicle transport assay, fumitremorgin C inhibition, competition assay","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1 — in vitro vesicle reconstitution with mutagenesis comparison","pmids":["14500392"],"is_preprint":false},{"year":2003,"finding":"ABCG2 transports sulfated conjugates of steroids and xenobiotics (estrone 3-sulfate, DHEAS, 4-methylumbelliferone sulfate, E3040 sulfate) in an ATP-dependent manner in membrane vesicles, with Km values of ~13–27 µM; transport is preferentially for sulfate conjugates over glucuronide and glutathione conjugates, suggesting physiological roles in steroid sulfate homeostasis.","method":"Inside-out membrane vesicle transport assay with radiolabeled substrates, inhibition studies","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstituted transport assay with multiple substrates and kinetic parameters","pmids":["12682043"],"is_preprint":false},{"year":2003,"finding":"Functional BCRP expressed in Xenopus laevis oocytes is a homodimer or homomultimer: mutations in the ATP-binding cassette signature motif (S187T or S187A) abolished transport activity despite high expression, and co-injection of dominant-negative S187T with active R482T suppressed transport in a dose-dependent manner; wild-type transported only mitoxantrone and flavopiridol, while R482T additionally transported daunorubicin and rhodamine 123.","method":"Xenopus oocyte heterologous expression, cRNA co-injection dominant-negative analysis, accumulation and efflux assays","journal":"Molecular pharmacology","confidence":"High","confidence_rationale":"Tier 1-2 — mutagenesis combined with dominant-negative co-injection in reconstituted system","pmids":["14645676"],"is_preprint":false},{"year":2003,"finding":"BCRP/ABCG2 was localized at the luminal surface of microvessel endothelium in human brain by immunofluorescence confocal microscopy and RT-PCR/Western blot, closely resembling the localization of P-gp, establishing BCRP as a component of the blood-brain barrier.","method":"RT-PCR, Western blotting, immunofluorescence confocal microscopy on human brain tissue","journal":"Neuroreport","confidence":"High","confidence_rationale":"Tier 2 — direct protein localization with multiple methods in human tissue; >320 citations","pmids":["12438926"],"is_preprint":false},{"year":2004,"finding":"ABCG2 binds heme and interacts with porphyrins; under hypoxia, Bcrp1(-/-) progenitor cells have reduced colony-forming ability, and this susceptibility is reversed by blocking heme biosynthesis; BCRP expression is transcriptionally upregulated by the HIF-1 hypoxia-inducible factor complex, positioning ABCG2 as a hypoxia-regulated porphyrin efflux transporter in stem cell survival.","method":"Knockout mouse progenitor colony assay, heme biosynthesis inhibition, HIF-1 reporter/ChIP-type analysis, binding assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal experiments including genetic rescue, substrate binding, transcriptional regulation; >500 citations","pmids":["15044468"],"is_preprint":false},{"year":2004,"finding":"Pheophorbide a (PhA) is an ABCG2-specific substrate; FTC-inhibitable PhA transport in cell lines correlates with ABCG2 surface expression (measured by anti-ABCG2 antibody 5D3), and transport is not observed in cells expressing P-glycoprotein or MRP1 alone, validating PhA as a specific ABCG2 probe.","method":"Flow cytometry transport assay, FTC inhibition, antibody 5D3 surface staining correlation","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — multiple cell lines with specific inhibitor control, replicated substrate identification","pmids":["14973080"],"is_preprint":false},{"year":2004,"finding":"SNP variants of BCRP/ABCG2 affect protein expression and localization: Q141K and S441N variants show significantly lower protein expression than wild type; S441N causes intracellular (non-apical) localization; the transport activity per unit protein (for E1S, DHEAS, MTX) is unchanged for Q141K, indicating the functional deficit is due to reduced protein expression/surface delivery rather than intrinsic catalytic deficiency.","method":"Transfection in LLC-PK1 and HEK293 cells, immunofluorescence localization, membrane vesicle transport assays, Western blot","journal":"Pharmaceutical research","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods including localization and quantitative transport per protein expression","pmids":["15553238"],"is_preprint":false},{"year":2005,"finding":"BCRP/ABCG2 mediates biliary excretion of the statin pitavastatin: ATP-dependent uptake was demonstrated in BCRP-expressing membrane vesicles (Km ~5.7 µM for human, ~4.8 µM for mouse), and biliary excretion clearance of pitavastatin in Bcrp1(-/-) mice was reduced to one-tenth of wild type, while MRP2-deficient rats showed no change.","method":"Membrane vesicle transport assay, Bcrp1(-/-) mouse in vivo biliary excretion, Eisai hyperbilirubinemic rat comparison, transcellular transport in MDCK double transfectants","journal":"Molecular pharmacology","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro vesicle reconstitution plus in vivo knockout confirmation","pmids":["15955871"],"is_preprint":false},{"year":2007,"finding":"Bcrp/ABCG2 limits the oral bioavailability and tissue distribution (brain, testis, epididymis, fetus) of phytoestrogens (daidzein, genistein, coumestrol): Bcrp(-/-) mice showed increased plasma levels after oral administration and significantly elevated brain and testis tissue-to-plasma ratios; Bcrp protein was localized to the luminal membrane of endothelial cells in testis and epididymis.","method":"Bcrp(-/-) knockout mouse pharmacokinetics, MDCK transfected cell transcellular transport, immunolocalization","journal":"Molecular pharmacology","confidence":"High","confidence_rationale":"Tier 2 — in vivo knockout pharmacokinetics plus in vitro reconstitution and direct localization","pmids":["17644650"],"is_preprint":false},{"year":2009,"finding":"ABCG2 is a urate efflux transporter located in the brush border membrane of kidney proximal tubule cells: functional assays confirmed ATP-dependent urate transport; the Q141K mutation (rs2231142) caused 53% reduction in urate transport rates; population data showed rs2231142 is causal for elevated serum urate and gout, attributing ≥10% of gout cases in whites to this variant.","method":"Site-directed mutagenesis, functional urate transport assay, kidney localization, population-based genetic association (14,783 individuals)","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — functional reconstitution with mutagenesis plus large population validation; >500 citations","pmids":["19506252"],"is_preprint":false},{"year":2009,"finding":"Common dysfunctional ABCG2 variants (Q141K, Q126X) essentially block gut and renal urate excretion, causing gout: urate transport assays confirmed ABCG2 is a high-capacity urate secretion transporter; 10% of gout patients had genotype combinations resulting in >75% reduction of ABCG2 function (OR 25.8).","method":"Urate transport assay, gene sequencing of hyperuricemia patients, quantitative trait locus analysis","journal":"Science translational medicine","confidence":"High","confidence_rationale":"Tier 1-2 — functional transport assay combined with large clinical cohort; >350 citations","pmids":["20368174"],"is_preprint":false},{"year":2010,"finding":"Structural analysis of purified human BCRP/ABCG2 by 2D electron crystallography at 5 Å resolution revealed an asymmetric ring-shaped transmembrane domain structure; in the absence of mitoxantrone, ABCG2 adopts a more open conformation, while in the presence of mitoxantrone, a more closed/compact conformation is observed, consistent with inward-facing substrate-bound and substrate-free states.","method":"Purification from Pichia pastoris, 2D crystallization, cryo-electron microscopy projection maps, homology modeling","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 — structural determination by electron crystallography with substrate-dependent conformational states","pmids":["20399185"],"is_preprint":false},{"year":2010,"finding":"ABCG2 knockdown (RNAi) in MCF-7/MX and A549 cancer cells significantly inhibited cell proliferation, reduced the S-phase fraction, and caused G0/G1 arrest associated with downregulation of cyclin D3 and upregulation of p21; chemical inhibition by fumitremorgin C produced a similar cell cycle effect, suggesting ABCG2 has a role in cell cycle progression beyond drug transport.","method":"RNA interference knockdown, flow cytometry cell cycle analysis, chemical inhibitor FTC, Western blot for cyclins","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2-3 — KD with defined phenotypic readout but mechanism only partially characterized","pmids":["19642144"],"is_preprint":false},{"year":2012,"finding":"Steroid hormones allosterically inhibit BCRP/ABCG2-mediated transport: estradiol, testosterone, progesterone, and androstenedione inhibited BCRP-mediated estrone sulfate uptake in membrane vesicles with Ki values of 5–217 µM through non-competitive (allosteric) inhibition; Bcrp is localized in the cortex of the adrenal gland and plasma membranes of adipocytes.","method":"Membrane vesicle transport assay with Ki determination, immunohistochemistry, quantitative PCR","journal":"Cell and tissue research","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro vesicle assay with kinetic analysis, single lab","pmids":["22581381"],"is_preprint":false},{"year":2013,"finding":"E2F1 transcription factor directly activates ABCG2 expression and drives chemotherapeutic drug resistance through ABCG2 in vitro and in vivo; E2F1-induced drug efflux was abrogated by ABCG2 inhibition, and a significant correlation between elevated E2F1 and ABCG2 expression was identified in human lung cancers.","method":"E2F1 overexpression and knockdown, luciferase reporter assay (direct promoter activation), in vivo xenograft, gene expression correlation in clinical samples","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — direct transcriptional regulation established with reporter assay and in vivo confirmation, single lab","pmids":["24276245"],"is_preprint":false},{"year":2015,"finding":"3D electron crystallography of full-length human ABCG2 without nucleotides or substrates revealed a symmetric homodimer in an inward-facing conformation with widely separated nucleotide-binding domains (NBDs), similar to murine ABCB1, and cytoplasmic extensions connecting TMDs to NBDs were resolved; this was the first 3D structure of full-length ABCG2.","method":"2D crystallization, electron crystallography, subtomogram averaging at ~2 nm resolution, homology model refinement","journal":"Acta crystallographica Section D","confidence":"High","confidence_rationale":"Tier 1 — first 3D structural determination of full-length ABCG2 confirmed by subtomogram averaging","pmids":["26249353"],"is_preprint":false},{"year":2016,"finding":"ABCG2 mediates androgen efflux in prostate stem cells (PSCs), maintaining an undifferentiated state: Ko143-mediated ABCG2 inhibition increased intracellular androgen levels, leading to nuclear AR translocation, upregulation of AR-regulated genes, and luminal differentiation; in vivo, Ko143 reduced tumor growth and increased percentage of differentiated CK8+/AR+ luminal cells.","method":"Ko143 pharmacological inhibition, siRNA knockdown, nuclear AR translocation assay, xenograft mouse model, immunohistochemistry","journal":"Molecular cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological inhibition with defined mechanistic readout in vitro and in vivo, single lab","pmids":["27856956"],"is_preprint":false},{"year":2016,"finding":"SIRT1 upregulates ABCG2 expression in the ileum through a PGC-1α/PPARγ signaling axis: resveratrol-activated SIRT1 deacetylated PGC-1α, which activated PPARγ to drive ABCG2 transcription; siRNA knockdown of PGC-1α or PPARγ abolished the SIRT1-induced upregulation of ABCG2, reducing serum uric acid in hyperuricemic mice.","method":"siRNA knockdown, resveratrol treatment, SIRT1 activation, Western blot, hyperuricemic mouse model","journal":"Endocrine","confidence":"Medium","confidence_rationale":"Tier 2-3 — epistasis established via siRNA in cell lines plus in vivo model, single lab","pmids":["27022940"],"is_preprint":false},{"year":2017,"finding":"High-resolution cryo-EM structure of human ABCG2 in complex with inhibitory antibody 5D3 Fab fragments was determined: two cholesterol molecules were found bound in the central hydrophobic multidrug-binding pocket within an inward-facing translocation pathway between transmembrane domains; structural data rationalized disease-causing SNPs, explained allosteric inhibition by 5D3 antibody, and revealed a cholesterol recognition mechanism shared with other G-subfamily ABC transporters.","method":"Cryo-electron microscopy (high-resolution), complex with 5D3 antibody Fab fragments, functional in vitro transport analyses","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — first high-resolution cryo-EM structure with functional validation; >340 citations","pmids":["28554189"],"is_preprint":false},{"year":2017,"finding":"Placental BCRP/ABCG2 expression is down-regulated by hypoxia: HIF-1α activation (by CoCl2 or 3% O2) reduced BCRP mRNA and protein by 30–75% in BeWo trophoblast cells and impaired substrate efflux activity; women at high altitude (chronic hypoxia) showed reduced BCRP in placental microvillous membranes correlating with elevated HIF-1α target expression.","method":"CoCl2 and hypoxia treatment, HIF-1α Western blot/ELISA, qPCR, fluorescent substrate transport assay, human placental tissue analysis","journal":"Placenta","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro mechanistic data confirmed with human clinical samples, single lab","pmids":["28292469"],"is_preprint":false},{"year":2008,"finding":"Lapatinib directly inhibits ABCG2 transport function: lapatinib stimulated ABCG2 ATPase activity, inhibited photolabeling of ABCG2 with [125I]iodoarylazidoprazosin in a concentration-dependent manner, inhibited ABCG2-mediated methotrexate and E217βG transport, increased mitoxantrone accumulation in ABCG2-overexpressing cells, and enhanced paclitaxel efficacy in ABCB1-overexpressing xenografts, without affecting transporter expression.","method":"ATPase stimulation assay, photoaffinity labeling, transport assay, accumulation assay, xenograft in vivo","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1-2 — multiple biochemical assays demonstrating direct drug-transporter interaction; >344 citations","pmids":["18829547"],"is_preprint":false},{"year":2004,"finding":"Imatinib mesylate (STI571) is a substrate for BCRP/ABCG2: imatinib competes with mitoxantrone for export in BCRP-overexpressing cell lines, and BCRP-mediated efflux is reversed by the fumitremorgin C analog Ko-143; this suggests BCRP can influence gastrointestinal absorption and cellular resistance to imatinib.","method":"Drug competition efflux assay, Ko-143 inhibition, multiple BCRP-overexpressing cell lines","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — substrate identification by competition assay with specific inhibitor, replicated across cell lines; >338 citations","pmids":["15251980"],"is_preprint":false},{"year":2007,"finding":"Pregnancy hormones regulate placental BCRP expression: estriol (E3), human placental lactogen (hPL), and prolactin (hPRL) increased BCRP protein and mRNA ~2–3-fold in BeWo cells; the inductive effect of E3 was abrogated by ER antagonist ICI-182,780; testosterone combined with E2 increased BCRP through E2-mediated upregulation of testosterone receptor (TR) mRNA; hCG had no effect.","method":"Hormone treatment in BeWo cells, immunoblotting, qRT-PCR, ER antagonist, siRNA knockdown of ERα, immunofluorescence","journal":"Pharmaceutical research","confidence":"Medium","confidence_rationale":"Tier 2-3 — receptor-mediated regulation established with antagonist and siRNA, single lab","pmids":["17823853"],"is_preprint":false},{"year":2008,"finding":"ABCG2 undergoes post-translational modifications including disulfide bond formation, ubiquitination, and ER-associated degradation that regulate its expression and trafficking; these modifications were identified as key determinants of ABCG2 protein stability and surface delivery.","method":"Biochemical characterization (disulfide bond analysis, ubiquitination assay, ER degradation experiments)","journal":"Xenobiotica","confidence":"Medium","confidence_rationale":"Tier 2-3 — PTM characterization reported, partially described in review context","pmids":["18668433"],"is_preprint":false},{"year":2010,"finding":"BCRP/Abcg2 plays a dominant role in intestinal genistein sulfate excretion: in Bcrp knockout mice, genistein sulfate excretion was reduced >90% in small intestine and became undetectable in colon; genistein glucuronide excretion also decreased significantly (78%), demonstrating that BCRP drives apical efflux of sulfated and glucuronidated isoflavone conjugates to prevent backward hydrolysis.","method":"Bcrp(-/-) knockout mouse intestinal perfusion model, LC/MS metabolite quantification, inhibitor studies","journal":"The AAPS journal","confidence":"High","confidence_rationale":"Tier 2 — in vivo knockout with direct metabolite quantification across two intestinal segments","pmids":["20582579"],"is_preprint":false}],"current_model":"ABCG2 (BCRP) is a homodimeric ABC half-transporter that hydrolyzes ATP to drive apical efflux of a broad range of substrates—including anticancer drugs, sulfated steroids, porphyrins, uric acid, and phytoestrogen conjugates—from cells at barrier tissues (intestine, liver canaliculi, placenta, blood-brain barrier, kidney proximal tubule); its substrate specificity is critically determined by residue 482 in the third transmembrane domain, its protein expression and trafficking are modulated by the Q141K SNP (which reduces surface delivery), and its transcription is regulated by HIF-1 under hypoxia, by the SIRT1/PGC-1α/PPARγ axis, and by E2F1, with high-resolution cryo-EM structures revealing an inward-facing homodimer with a central hydrophobic multidrug-binding pocket where cholesterol and substrates bind before ATP-driven translocation."},"narrative":{"teleology":[{"year":1998,"claim":"The identification of ABCG2 as a novel half-transporter overexpressed in multidrug-resistant breast cancer cells established it as an ATP-dependent xenobiotic efflux pump, resolving the molecular basis of a mitoxantrone-resistance phenotype that was not attributable to P-gp or MRP1.","evidence":"cDNA cloning from MCF-7/AdrVp cells with drug accumulation/efflux assays and independent cloning from placenta","pmids":["9861027","9850061"],"confidence":"High","gaps":["No structural information","Full substrate range unknown","Endogenous physiological substrates not identified"]},{"year":2001,"claim":"Mapping of ABCG2 to apical membranes of barrier epithelia (intestine, liver canaliculi, placenta, brain endothelium) and its identification as the molecular determinant of the hematopoietic side-population phenotype established its dual role as a pharmacological gatekeeper and stem cell marker.","evidence":"Immunohistochemistry with two independent antibodies across human tissues; retroviral transduction and transplantation assays in bone marrow cells; Hoechst 33342 efflux in transduced MCF-7 cells","pmids":["11309308","11533706","11801536"],"confidence":"High","gaps":["Mechanism linking ABCG2 expression to stemness beyond dye efflux unclear","Blood–brain barrier functional significance not quantified in vivo at this stage"]},{"year":2001,"claim":"Demonstrating that residue 482 governs substrate specificity resolved why different drug-selected cell lines showed discordant resistance profiles and provided the first structure–function insight into the transmembrane drug-binding site.","evidence":"Sequencing of resistant lines, site-directed mutagenesis, vaccinia virus expression system with drug efflux and cytotoxicity assays","pmids":["11559526"],"confidence":"High","gaps":["No atomic-level explanation for how position 482 alters binding pocket geometry","Only a few substrates tested at this point"]},{"year":2002,"claim":"Knockout mice revealed essential physiological roles for ABCG2 in porphyrin homeostasis and protection from dietary phototoxins, demonstrating that ABCG2 is not merely a drug-resistance factor but a guardian against endogenous and dietary toxins.","evidence":"Bcrp1−/− mice developed phototoxic lesions and protoporphyria; bone marrow transplant from wild-type donors rescued the phenotype","pmids":["12429862"],"confidence":"High","gaps":["Full spectrum of endogenous substrates beyond porphyrins not yet defined","Tissue-specific contributions (erythroid vs. hepatic) incompletely resolved"]},{"year":2003,"claim":"Reconstituted vesicle transport assays quantified ATP-dependent transport of methotrexate, sulfated steroids (estrone 3-sulfate, DHEAS), and xenobiotic sulfate conjugates, establishing ABCG2 as a major sulfate conjugate transporter with defined kinetic parameters.","evidence":"Inside-out membrane vesicle assays with radiolabeled substrates, Km determination, and position-482 mutagenesis comparison","pmids":["14500392","12682043"],"confidence":"High","gaps":["Glucuronide and glutathione conjugate transport appeared minor but was not systematically evaluated","In vivo relevance of steroid sulfate transport not yet demonstrated"]},{"year":2003,"claim":"Dominant-negative co-injection experiments in Xenopus oocytes proved that ABCG2 functions as a homodimer (or homomultimer), establishing the minimal functional unit required for transport.","evidence":"Co-injection of signature-motif mutant (S187T) cRNA with wild-type cRNA in Xenopus oocytes, dose-dependent suppression of transport","pmids":["14645676"],"confidence":"High","gaps":["No direct cross-linking or analytical ultracentrifugation data at this stage","Whether higher-order oligomers exist in native membranes unresolved"]},{"year":2004,"claim":"Characterization of the Q141K polymorphism revealed that its functional deficit arises from reduced protein expression and impaired surface trafficking rather than altered catalytic activity, explaining variable drug pharmacokinetics in carriers.","evidence":"Transfection in LLC-PK1 and HEK293 cells with quantitative transport normalized to protein expression, immunofluorescence localization of SNP variants","pmids":["15553238","12479221"],"confidence":"High","gaps":["Molecular mechanism of Q141K-mediated protein instability (ubiquitination, ER retention) not fully elucidated","Population-level pharmacokinetic consequences only partially quantified"]},{"year":2004,"claim":"Discovery that HIF-1α transcriptionally upregulates ABCG2 and that ABCG2 binds heme linked the transporter to hypoxia signaling and hematopoietic progenitor survival, explaining why stem cells expressing ABCG2 are protected under low-oxygen conditions.","evidence":"Bcrp1−/− progenitor colony assays under hypoxia, heme biosynthesis blockade rescue, HIF-1 reporter analysis","pmids":["15044468"],"confidence":"High","gaps":["Whether HIF-1α acts on ABCG2 promoter directly or indirectly not fully resolved by ChIP at this stage","Relative contribution of porphyrin efflux vs. other substrates to stem cell protection unclear"]},{"year":2009,"claim":"Identification of ABCG2 as a renal urate efflux transporter, with Q141K causing 53% reduced transport, established a causal link between ABCG2 dysfunction, hyperuricemia, and gout—attributing ≥10% of gout cases in European-descent populations to this variant.","evidence":"Functional urate transport assay with site-directed mutagenesis, kidney brush-border localization, population genetic association in 14,783 individuals","pmids":["19506252","20368174"],"confidence":"High","gaps":["Relative contribution of intestinal vs. renal ABCG2 to total urate excretion debated","Therapeutic strategies targeting ABCG2-mediated urate transport not developed"]},{"year":2010,"claim":"Low-resolution electron crystallography provided the first 3D structural view of ABCG2, revealing an inward-facing homodimer with separated NBDs and substrate-dependent conformational changes, bridging the gap between biochemical data and structural biology.","evidence":"2D crystallization and cryo-EM projection maps of purified ABCG2 from Pichia pastoris, with and without mitoxantrone","pmids":["20399185","26249353"],"confidence":"High","gaps":["Resolution too low to identify substrate-binding residues","Outward-facing conformation not captured"]},{"year":2017,"claim":"The first high-resolution cryo-EM structure of ABCG2 (with 5D3 Fab) identified two cholesterol molecules in the central multidrug-binding pocket, providing an atomic-level framework for understanding polyspecific substrate recognition, allosteric inhibition, and the structural basis of disease-causing SNPs.","evidence":"Cryo-EM of ABCG2–5D3 Fab complex at near-atomic resolution with functional transport validation","pmids":["28554189"],"confidence":"High","gaps":["Structures with diverse drug substrates bound (e.g., urate, methotrexate) not yet reported in this timeline","Outward-facing ATP-bound state not captured","Mechanism of cholesterol modulation of transport cycle incompletely understood"]},{"year":null,"claim":"Key unresolved questions include the complete conformational cycle of ABCG2 during ATP-driven transport, the structural basis by which residue 482 mutations alter substrate selectivity at atomic resolution, the relative physiological contributions of intestinal versus renal ABCG2 to urate homeostasis, and whether ABCG2's effect on cell cycle progression reflects direct transport of an endogenous signaling substrate.","evidence":"","pmids":[],"confidence":"Low","gaps":["Full transport cycle intermediates not structurally resolved","Endogenous signaling substrates linking ABCG2 to cell cycle regulation unidentified","Tissue-specific conditional knockouts needed to delineate organ-level contributions"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[0,5,10,11,19]},{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[0,2,10,11,17,19,34]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[7,13,16,19]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[33]}],"pathway":[{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[0,2,10,11,17,19,20]},{"term_id":"R-HSA-9748784","term_label":"Drug ADME","supporting_discovery_ids":[17,30,31]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[8,11,19,34]}],"complexes":["ABCG2 homodimer"],"partners":["HIF1A","PPARG","PPARGC1A","SIRT1","E2F1"],"other_free_text":[]},"mechanistic_narrative":"ABCG2 (BCRP/MXR) is a homodimeric ABC half-transporter that couples ATP hydrolysis to the apical efflux of a remarkably broad substrate repertoire—including anticancer drugs, porphyrins, sulfated steroid conjugates, uric acid, phytoestrogens, and statins—at pharmacological barrier tissues such as the intestinal epithelium, liver canaliculi, placental syncytiotrophoblast, kidney proximal tubule, and blood–brain barrier endothelium [PMID:9861027, PMID:11309308, PMID:12438926, PMID:19506252]. Substrate specificity is critically governed by residue Arg482 in the third transmembrane segment, where acquired mutations broaden the transported drug spectrum, while the common Q141K polymorphism reduces surface protein levels—without altering intrinsic catalytic activity—leading to impaired urate secretion and clinically significant hyperuricemia and gout [PMID:11559526, PMID:15553238, PMID:20368174]. High-resolution cryo-EM structures reveal an inward-facing homodimer with a central hydrophobic multidrug-binding pocket occupied by cholesterol molecules, rationalizing the polyspecific binding mechanism and allosteric inhibition by antibodies and pharmacological agents [PMID:28554189]. ABCG2 expression is transcriptionally regulated by HIF-1α under hypoxia, the SIRT1–PGC-1α–PPARγ axis, and E2F1, and the transporter defines the hematopoietic side-population stem cell phenotype through Hoechst 33342 and porphyrin efflux, protecting progenitor cells from phototoxic and oxidative damage [PMID:15044468, PMID:11533706, PMID:12429862, PMID:24276245]."},"prefetch_data":{"uniprot":{"accession":"Q9UNQ0","full_name":"Broad substrate specificity ATP-binding cassette transporter ABCG2","aliases":["ATP-binding cassette sub-family G member 2","Breast cancer resistance protein","CDw338","Mitoxantrone resistance-associated protein","Placenta-specific ATP-binding cassette transporter","Urate exporter"],"length_aa":655,"mass_kda":72.3,"function":"Broad substrate specificity ATP-dependent transporter of the ATP-binding cassette (ABC) family that actively extrudes a wide variety of physiological compounds, dietary toxins and xenobiotics from cells (PubMed:11306452, PubMed:12958161, PubMed:19506252, PubMed:20705604, PubMed:28554189, PubMed:30405239, PubMed:31003562). Involved in porphyrin homeostasis, mediating the export of protoporphyrin IX (PPIX) from both mitochondria to cytosol and cytosol to extracellular space, it also functions in the cellular export of heme (PubMed:20705604, PubMed:23189181). Also mediates the efflux of sphingosine-1-P from cells (PubMed:20110355). Acts as a urate exporter functioning in both renal and extrarenal urate excretion (PubMed:19506252, PubMed:20368174, PubMed:22132962, PubMed:31003562, PubMed:36749388). In kidney, it also functions as a physiological exporter of the uremic toxin indoxyl sulfate (By similarity). Also involved in the excretion of steroids like estrone 3-sulfate/E1S, 3beta-sulfooxy-androst-5-en-17-one/DHEAS, and other sulfate conjugates (PubMed:12682043, PubMed:28554189, PubMed:30405239). Mediates the secretion of the vitamins riboflavin and biotin into milk (By similarity). Involved in the excretion of the riboflavin-derived compound lumichrome into the intestinal lumen and in its secretion into milk (PubMed:39337371). Extrudes pheophorbide a, a phototoxic porphyrin catabolite of chlorophyll, reducing its bioavailability (By similarity). Plays an important role in the exclusion of xenobiotics from the brain (Probable). It confers to cells a resistance to multiple drugs and other xenobiotics including mitoxantrone, pheophorbide, camptothecin, methotrexate, azidothymidine, and the anthracyclines daunorubicin and doxorubicin, through the control of their efflux (PubMed:11306452, PubMed:12477054, PubMed:15670731, PubMed:18056989, PubMed:31254042). In placenta, it limits the penetration of drugs from the maternal plasma into the fetus (By similarity). May play a role in early stem cell self-renewal by blocking differentiation (By similarity). In inflammatory macrophages, exports itaconate from the cytosol to the extracellular compartment and limits the activation of TFEB-dependent lysosome biogenesis involved in antibacterial innate immune response","subcellular_location":"Cell membrane; Apical cell membrane; Mitochondrion membrane","url":"https://www.uniprot.org/uniprotkb/Q9UNQ0/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ABCG2","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ABCG2","total_profiled":1310},"omim":[{"mim_id":"618807","title":"LIPOPROTEIN(a) QUANTITATIVE TRAIT LOCUS; LPAQTL","url":"https://www.omim.org/entry/618807"},{"mim_id":"614755","title":"MICRO RNA 520H; MIR520H","url":"https://www.omim.org/entry/614755"},{"mim_id":"614490","title":"BLOOD GROUP, JUNIOR SYSTEM; JR","url":"https://www.omim.org/entry/614490"},{"mim_id":"613095","title":"POLYCYSTIC KIDNEY DISEASE 2 WITH OR WITHOUT POLYCYSTIC LIVER DISEASE; PKD2","url":"https://www.omim.org/entry/613095"},{"mim_id":"607948","title":"MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/607948"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"intestine","ntpm":83.2}],"url":"https://www.proteinatlas.org/search/ABCG2"},"hgnc":{"alias_symbol":["EST157481","MXR","BCRP","ABCP","CD338"],"prev_symbol":[]},"alphafold":{"accession":"Q9UNQ0","domains":[{"cath_id":"-","chopping":"372-593_603-649","consensus_level":"high","plddt":92.3426,"start":372,"end":649}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UNQ0","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UNQ0-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UNQ0-F1-predicted_aligned_error_v6.png","plddt_mean":85.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ABCG2","jax_strain_url":"https://www.jax.org/strain/search?query=ABCG2"},"sequence":{"accession":"Q9UNQ0","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9UNQ0.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9UNQ0/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UNQ0"}},"corpus_meta":[{"pmid":"15845415","id":"PMC_15845415","title":"Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense.","date":"2005","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15845415","citation_count":1086,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14576842","id":"PMC_14576842","title":"Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/14576842","citation_count":815,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9850061","id":"PMC_9850061","title":"A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance.","date":"1998","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9850061","citation_count":670,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11497241","id":"PMC_11497241","title":"From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance.","date":"2001","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/11497241","citation_count":566,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25236865","id":"PMC_25236865","title":"Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.","date":"2014","source":"The AAPS journal","url":"https://pubmed.ncbi.nlm.nih.gov/25236865","citation_count":497,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10493507","id":"PMC_10493507","title":"Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.","date":"1999","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/10493507","citation_count":434,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10806112","id":"PMC_10806112","title":"The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2).","date":"2000","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/10806112","citation_count":418,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19135109","id":"PMC_19135109","title":"ABCG2: a perspective.","date":"2008","source":"Advanced drug delivery reviews","url":"https://pubmed.ncbi.nlm.nih.gov/19135109","citation_count":372,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11559526","id":"PMC_11559526","title":"Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.","date":"2001","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11559526","citation_count":368,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28554189","id":"PMC_28554189","title":"Structure of the human multidrug transporter ABCG2.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28554189","citation_count":340,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22248732","id":"PMC_22248732","title":"Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.","date":"2012","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22248732","citation_count":321,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11205902","id":"PMC_11205902","title":"Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.","date":"2001","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/11205902","citation_count":310,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14973080","id":"PMC_14973080","title":"Pheophorbide a is a specific probe for ABCG2 function and inhibition.","date":"2004","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/14973080","citation_count":303,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16146333","id":"PMC_16146333","title":"Role of the breast cancer resistance protein (ABCG2) in drug transport.","date":"2005","source":"The AAPS journal","url":"https://pubmed.ncbi.nlm.nih.gov/16146333","citation_count":294,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16402910","id":"PMC_16402910","title":"Role of ABCG2/BCRP in biology and medicine.","date":"2006","source":"Annual review of pharmacology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/16402910","citation_count":278,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12682043","id":"PMC_12682043","title":"ABCG2 transports sulfated conjugates of steroids and xenobiotics.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12682043","citation_count":236,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10606239","id":"PMC_10606239","title":"Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.","date":"1999","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/10606239","citation_count":223,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11406094","id":"PMC_11406094","title":"A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2).","date":"2001","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/11406094","citation_count":223,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15955871","id":"PMC_15955871","title":"Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin.","date":"2005","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15955871","citation_count":212,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15553238","id":"PMC_15553238","title":"Functional analysis of SNPs variants of BCRP/ABCG2.","date":"2004","source":"Pharmaceutical research","url":"https://pubmed.ncbi.nlm.nih.gov/15553238","citation_count":198,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17148776","id":"PMC_17148776","title":"Pharmacogenetics of ABCG2 and adverse reactions to gefitinib.","date":"2006","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/17148776","citation_count":187,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14500392","id":"PMC_14500392","title":"Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter.","date":"2003","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/14500392","citation_count":182,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24021215","id":"PMC_24021215","title":"Molecular pharmacology of ABCG2 and its role in chemoresistance.","date":"2013","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24021215","citation_count":181,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18370855","id":"PMC_18370855","title":"ABCG2: structure, function and role in drug response.","date":"2008","source":"Expert opinion on drug metabolism & toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/18370855","citation_count":175,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19544374","id":"PMC_19544374","title":"Modulation of the activity of ABC transporters (P-glycoprotein, MRP2, BCRP) by flavonoids and drug response.","date":"2010","source":"Journal of pharmaceutical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/19544374","citation_count":170,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17202245","id":"PMC_17202245","title":"Modulation of human BCRP (ABCG2) activity by anti-HIV drugs.","date":"2007","source":"The Journal of antimicrobial chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/17202245","citation_count":163,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15694832","id":"PMC_15694832","title":"Breast cancer resistance protein (BCRP/ABCG2).","date":"2005","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/15694832","citation_count":158,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19165709","id":"PMC_19165709","title":"ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS.","date":"2009","source":"Neuropediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/19165709","citation_count":145,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19629677","id":"PMC_19629677","title":"Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier.","date":"2009","source":"Cellular and molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/19629677","citation_count":144,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17644650","id":"PMC_17644650","title":"Effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of phytoestrogens.","date":"2007","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17644650","citation_count":132,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12488537","id":"PMC_12488537","title":"Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors.","date":"2003","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12488537","citation_count":121,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26148857","id":"PMC_26148857","title":"The Inhibitor Ko143 Is Not Specific for ABCG2.","date":"2015","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/26148857","citation_count":119,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19111841","id":"PMC_19111841","title":"Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy.","date":"2008","source":"Advanced drug delivery reviews","url":"https://pubmed.ncbi.nlm.nih.gov/19111841","citation_count":114,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10930538","id":"PMC_10930538","title":"BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells.","date":"2000","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/10930538","citation_count":109,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34586444","id":"PMC_34586444","title":"Multidrug efflux transporter ABCG2: expression and regulation.","date":"2021","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/34586444","citation_count":100,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14618629","id":"PMC_14618629","title":"Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.","date":"2004","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/14618629","citation_count":99,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17906686","id":"PMC_17906686","title":"The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids.","date":"2007","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17906686","citation_count":98,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16247709","id":"PMC_16247709","title":"BCRP transports dipyridamole and is inhibited by calcium channel blockers.","date":"2005","source":"Pharmaceutical research","url":"https://pubmed.ncbi.nlm.nih.gov/16247709","citation_count":97,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18253130","id":"PMC_18253130","title":"Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors.","date":"2008","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/18253130","citation_count":96,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15703302","id":"PMC_15703302","title":"Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2).","date":"2005","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/15703302","citation_count":92,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12642696","id":"PMC_12642696","title":"Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ABCP1).","date":"2002","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/12642696","citation_count":89,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23497885","id":"PMC_23497885","title":"Identification of novel dietary phytochemicals inhibiting the efflux transporter breast cancer resistance protein (BCRP/ABCG2).","date":"2012","source":"Food chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23497885","citation_count":82,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16158227","id":"PMC_16158227","title":"The ABC transporter Abcg2/Bcrp: role in hypoxia mediated survival.","date":"2005","source":"Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16158227","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26714461","id":"PMC_26714461","title":"New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies.","date":"2015","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/26714461","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22673043","id":"PMC_22673043","title":"Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics.","date":"2012","source":"Drug metabolism and pharmacokinetics","url":"https://pubmed.ncbi.nlm.nih.gov/22673043","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12100141","id":"PMC_12100141","title":"Expression of the BCRP gene (ABCG2/MXR/ABCP) in childhood acute lymphoblastic leukaemia.","date":"2002","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/12100141","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29031817","id":"PMC_29031817","title":"BCRP/ABCG2 and high-alert medications: Biochemical, pharmacokinetic, pharmacogenetic, and clinical implications.","date":"2017","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29031817","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21731744","id":"PMC_21731744","title":"Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21731744","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10856437","id":"PMC_10856437","title":"Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of (99m)Tc-tetrofosmin.","date":"2000","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/10856437","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18464048","id":"PMC_18464048","title":"Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2).","date":"2008","source":"Drug metabolism reviews","url":"https://pubmed.ncbi.nlm.nih.gov/18464048","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21139040","id":"PMC_21139040","title":"The bioflavonoid kaempferol is an Abcg2 substrate and inhibits Abcg2-mediated quercetin efflux.","date":"2010","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/21139040","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21118093","id":"PMC_21118093","title":"The challenge of exploiting ABCG2 in the clinic.","date":"2011","source":"Current pharmaceutical biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/21118093","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21103975","id":"PMC_21103975","title":"In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2).","date":"2011","source":"Handbook of experimental pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/21103975","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20399185","id":"PMC_20399185","title":"The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone.","date":"2010","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/20399185","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21884024","id":"PMC_21884024","title":"The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins.","date":"2011","source":"Cardiovascular therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/21884024","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28005280","id":"PMC_28005280","title":"ABCG2/BCRP: Specific and Nonspecific Modulators.","date":"2016","source":"Medicinal research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/28005280","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15210293","id":"PMC_15210293","title":"Regulation of expression of multixenobiotic resistance (MXR) genes by environmental factors in the blue mussel Mytilus edulis.","date":"2004","source":"Aquatic toxicology (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/15210293","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14645676","id":"PMC_14645676","title":"Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis.","date":"2003","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/14645676","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35483322","id":"PMC_35483322","title":"Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.","date":"2022","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35483322","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16554028","id":"PMC_16554028","title":"Down-regulation of BCRP/ABCG2 in colorectal and cervical cancer.","date":"2006","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16554028","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20582579","id":"PMC_20582579","title":"Breast cancer resistance protein (BCRP) and sulfotransferases contribute significantly to the disposition of genistein in mouse intestine.","date":"2010","source":"The AAPS journal","url":"https://pubmed.ncbi.nlm.nih.gov/20582579","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10958952","id":"PMC_10958952","title":"Seasonal variation of MXR and stress proteins in the common mussel, Mytilus galloprovincialis.","date":"2000","source":"Aquatic toxicology (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/10958952","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31384528","id":"PMC_31384528","title":"Development of precision medicine approaches based on inter-individual variability of BCRP/ABCG2.","date":"2019","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/31384528","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17375082","id":"PMC_17375082","title":"The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2).","date":"2007","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17375082","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18681776","id":"PMC_18681776","title":"Pharmacogenomic importance of ABCG2.","date":"2008","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/18681776","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19642144","id":"PMC_19642144","title":"Suppression of ABCG2 inhibits cancer cell proliferation.","date":"2010","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19642144","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26197160","id":"PMC_26197160","title":"Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.","date":"2015","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26197160","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33015850","id":"PMC_33015850","title":"The ABCG2/BCRP transporter and its variants - from structure to pathology.","date":"2020","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/33015850","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12082458","id":"PMC_12082458","title":"Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2.","date":"2002","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/12082458","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21425956","id":"PMC_21425956","title":"Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.","date":"2011","source":"Xenobiotica; the fate of foreign compounds in biological systems","url":"https://pubmed.ncbi.nlm.nih.gov/21425956","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26557010","id":"PMC_26557010","title":"Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology.","date":"2015","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/26557010","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30856014","id":"PMC_30856014","title":"ABCG2/BCRP: variants, transporter interaction profile of substrates and inhibitors.","date":"2019","source":"Expert opinion on drug metabolism & toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/30856014","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27022940","id":"PMC_27022940","title":"SIRT1 prevents hyperuricemia via the PGC-1α/PPARγ-ABCG2 pathway.","date":"2016","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/27022940","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24486881","id":"PMC_24486881","title":"First evidence for toxic defense based on the multixenobiotic resistance (MXR) mechanism in Daphnia magna.","date":"2014","source":"Aquatic toxicology (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/24486881","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17237154","id":"PMC_17237154","title":"Identification and functional assessment of BCRP polymorphisms in a Korean population.","date":"2007","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/17237154","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22581381","id":"PMC_22581381","title":"Localization of breast cancer resistance protein (Bcrp) in endocrine organs and inhibition of its transport activity by steroid hormones.","date":"2012","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/22581381","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17425799","id":"PMC_17425799","title":"Molecular and cellular characterization of ABCG2 in the prostate.","date":"2007","source":"BMC urology","url":"https://pubmed.ncbi.nlm.nih.gov/17425799","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20159988","id":"PMC_20159988","title":"Breast cancer resistance protein (BCRP)-mediated glyburide transport: effect of the C421A/Q141K BCRP single-nucleotide polymorphism.","date":"2010","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/20159988","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22401348","id":"PMC_22401348","title":"Breast cancer resistance protein (BCRP/ABCG2) localises to the nucleus in glioblastoma multiforme cells.","date":"2012","source":"Xenobiotica; the fate of foreign compounds in biological systems","url":"https://pubmed.ncbi.nlm.nih.gov/22401348","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18450391","id":"PMC_18450391","title":"Role of breast cancer resistance protein (Bcrp/Abcg2) in fetal protection during gestation in rat.","date":"2008","source":"Toxicology letters","url":"https://pubmed.ncbi.nlm.nih.gov/18450391","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19172464","id":"PMC_19172464","title":"Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells.","date":"2009","source":"Current eye research","url":"https://pubmed.ncbi.nlm.nih.gov/19172464","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18598762","id":"PMC_18598762","title":"Modulation of breast cancer resistance protein (BCRP/ABCG2) by non-basic chalcone analogues.","date":"2008","source":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/18598762","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26149077","id":"PMC_26149077","title":"Enhanced efficacy of photodynamic therapy by inhibiting ABCG2 in colon cancers.","date":"2015","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26149077","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24276245","id":"PMC_24276245","title":"E2F1 drives chemotherapeutic drug resistance via ABCG2.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24276245","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19146924","id":"PMC_19146924","title":"Interactions between riluzole and ABCG2/BCRP transporter.","date":"2009","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/19146924","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35582565","id":"PMC_35582565","title":"Recent advances in the search of BCRP- and dual P-gp/BCRP-based multidrug resistance modulators.","date":"2019","source":"Cancer drug resistance (Alhambra, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/35582565","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21133588","id":"PMC_21133588","title":"Expression of ABCG2 and its significance in colorectal cancer.","date":"2010","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/21133588","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27856956","id":"PMC_27856956","title":"The Efflux Transporter ABCG2 Maintains Prostate Stem Cells.","date":"2016","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/27856956","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21645015","id":"PMC_21645015","title":"ABCG2 transporter: therapeutic and physiologic implications in veterinary species.","date":"2011","source":"Journal of veterinary pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/21645015","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28292469","id":"PMC_28292469","title":"Down-regulation of the placental BCRP/ABCG2 transporter in response to hypoxia signaling.","date":"2017","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/28292469","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17823853","id":"PMC_17823853","title":"Hormonal regulation of BCRP expression in human placental BeWo cells.","date":"2007","source":"Pharmaceutical research","url":"https://pubmed.ncbi.nlm.nih.gov/17823853","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24269959","id":"PMC_24269959","title":"Dietary polyacetylenes of the falcarinol type are inhibitors of breast cancer resistance protein (BCRP/ABCG2).","date":"2013","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24269959","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16279786","id":"PMC_16279786","title":"Piperazinobenzopyranones and phenalkylaminobenzopyranones: potent inhibitors of breast cancer resistance protein (ABCG2).","date":"2005","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16279786","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30392788","id":"PMC_30392788","title":"Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer.","date":"2018","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/30392788","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18668433","id":"PMC_18668433","title":"Human ABC transporters ABCG2 (BCRP) and ABCG4.","date":"2008","source":"Xenobiotica; the fate of foreign compounds in biological systems","url":"https://pubmed.ncbi.nlm.nih.gov/18668433","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32077332","id":"PMC_32077332","title":"Transcription factor-mediated regulation of the BCRP/ABCG2 efflux transporter: a review across tissues and species.","date":"2020","source":"Expert opinion on drug metabolism & toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/32077332","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28619281","id":"PMC_28619281","title":"Metabolism of KO143, an ABCG2 inhibitor.","date":"2017","source":"Drug metabolism and pharmacokinetics","url":"https://pubmed.ncbi.nlm.nih.gov/28619281","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32554246","id":"PMC_32554246","title":"SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.","date":"2020","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/32554246","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26249353","id":"PMC_26249353","title":"Three-dimensional structure of the human breast cancer resistance protein (BCRP/ABCG2) in an inward-facing conformation.","date":"2015","source":"Acta crystallographica. Section D, Biological crystallography","url":"https://pubmed.ncbi.nlm.nih.gov/26249353","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36529162","id":"PMC_36529162","title":"Novel inhibitors of breast cancer resistance protein (BCRP, ABCG2) among marketed drugs.","date":"2022","source":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36529162","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11533706","id":"PMC_11533706","title":"The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype.","date":"2001","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11533706","citation_count":1819,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9861027","id":"PMC_9861027","title":"A multidrug resistance transporter from human MCF-7 breast cancer cells.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9861027","citation_count":1789,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"30280653","id":"PMC_30280653","title":"Blood-Brain Barrier: From Physiology to Disease and Back.","date":"2019","source":"Physiological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/30280653","citation_count":1645,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26590417","id":"PMC_26590417","title":"Establishment and Dysfunction of the Blood-Brain Barrier.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26590417","citation_count":1304,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11309308","id":"PMC_11309308","title":"Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.","date":"2001","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11309308","citation_count":928,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14702039","id":"PMC_14702039","title":"Complete sequencing and characterization of 21,243 full-length human cDNAs.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14702039","citation_count":754,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16024622","id":"PMC_16024622","title":"Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic.","date":"2005","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16024622","citation_count":724,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9892175","id":"PMC_9892175","title":"Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes.","date":"1999","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9892175","citation_count":681,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23263486","id":"PMC_23263486","title":"Genome-wide association analyses identify 18 new loci associated with serum urate concentrations.","date":"2012","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23263486","citation_count":657,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12429862","id":"PMC_12429862","title":"The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12429862","citation_count":631,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18834626","id":"PMC_18834626","title":"Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study.","date":"2008","source":"Lancet (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/18834626","citation_count":551,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15044468","id":"PMC_15044468","title":"The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15044468","citation_count":526,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19506252","id":"PMC_19506252","title":"Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19506252","citation_count":525,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19503597","id":"PMC_19503597","title":"Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations.","date":"2009","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19503597","citation_count":506,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20360068","id":"PMC_20360068","title":"Systematic analysis of human protein complexes identifies chromosome segregation proteins.","date":"2010","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/20360068","citation_count":421,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20139978","id":"PMC_20139978","title":"Genome-wide association study of hematological and biochemical traits in a Japanese population.","date":"2010","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20139978","citation_count":406,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12479221","id":"PMC_12479221","title":"C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.","date":"2002","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/12479221","citation_count":378,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20368174","id":"PMC_20368174","title":"Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population.","date":"2009","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20368174","citation_count":350,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18829547","id":"PMC_18829547","title":"Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18829547","citation_count":344,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15251980","id":"PMC_15251980","title":"Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15251980","citation_count":338,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12438926","id":"PMC_12438926","title":"Localisation of breast cancer resistance protein in microvessel endothelium of human brain.","date":"2002","source":"Neuroreport","url":"https://pubmed.ncbi.nlm.nih.gov/12438926","citation_count":322,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19474787","id":"PMC_19474787","title":"ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.","date":"2009","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/19474787","citation_count":320,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11801536","id":"PMC_11801536","title":"The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.","date":"2002","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/11801536","citation_count":319,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17323127","id":"PMC_17323127","title":"ABCG2: determining its relevance in clinical drug resistance.","date":"2007","source":"Cancer metastasis reviews","url":"https://pubmed.ncbi.nlm.nih.gov/17323127","citation_count":313,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21707071","id":"PMC_21707071","title":"Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels.","date":"2011","source":"Molecular pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/21707071","citation_count":308,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49775,"output_tokens":5982,"usd":0.119527},"stage2":{"model":"claude-opus-4-6","input_tokens":9653,"output_tokens":3421,"usd":0.200685},"total_usd":0.692713,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":64089,"output_tokens":8424,"usd":0.159313},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":12535,"output_tokens":3178,"usd":0.213188}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2017,\n      \"finding\": \"Cryo-EM structure of human ABCG2 in complex with two antigen-binding fragments of the inhibitory antibody 5D3 revealed two cholesterol molecules bound in a central, hydrophobic, inward-facing multidrug-binding pocket between the transmembrane domains, and provided structural basis for multidrug recognition, transport mechanism, rationalization of disease-causing SNPs, and allosteric inhibition by 5D3.\",\n      \"method\": \"Cryo-electron microscopy structure determination combined with functional in vitro analyses\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution cryo-EM structure with functional validation in a single rigorous study\",\n      \"pmids\": [\"28554189\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Three-dimensional electron crystallography of full-length human ABCG2 revealed a symmetric homodimer in an inward-facing conformation with widely separated nucleotide-binding domains, consistent with a substrate-free state.\",\n      \"method\": \"Electron crystallography from 2D crystals; subtomogram averaging\",\n      \"journal\": \"Acta crystallographica. Section D, Biological crystallography\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct structural determination with atomic model refinement validated against prior mutagenesis data\",\n      \"pmids\": [\"26249353\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Purified ABCG2 reconstituted into 2D crystals showed conformational changes upon mitoxantrone binding by cryo-EM projection maps: an open, less-symmetric structure without substrate and a more closed form with mitoxantrone, consistent with substrate-induced closure of the inward-facing conformation.\",\n      \"method\": \"2D crystallization of Pichia pastoris-expressed ABCG2; cryo-EM projection mapping with and without mitoxantrone; homology modeling\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted purified protein, structural data with functional interpretation\",\n      \"pmids\": [\"20399185\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The amino acid at position 482 of ABCG2 is critical for substrate specificity: wild-type Arg482 does not transport rhodamine 123 or doxorubicin, whereas acquired Thr482 or Gly482 mutations enable their transport while all three variants transport mitoxantrone. A vaccinia virus expression system confirmed these substrate specificity differences.\",\n      \"method\": \"Gene sequencing of drug-resistant cell lines; vaccinia virus expression system; transport/efflux assays; cytotoxicity assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — site-specific mutagenesis with functional reconstitution in expression system, replicated across multiple cell lines\",\n      \"pmids\": [\"11559526\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Wild-type ABCG2 (Arg482) functions as an ATP-dependent transporter of methotrexate (MTX) and its polyglutamates (MTX-Glu2, MTX-Glu3) in inside-out membrane vesicles; the mutant Gly482 variant does not transport MTX, establishing that the 482 residue determines MTX transport competence.\",\n      \"method\": \"Inside-out membrane vesicle transport assay with ATP dependence and inhibitor controls; comparison of wild-type vs. mutant BCRP-expressing vesicles\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstituted vesicle transport assay with mutagenesis comparison\",\n      \"pmids\": [\"14500392\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ABCG2 (wild-type) actively transports sulfated conjugates of steroids and xenobiotics including estrone 3-sulfate (Km=16.6 µM), DHEAS, and 4-methylumbelliferone sulfate in an ATP-dependent manner; sulfate conjugates are preferred over glucuronide or glutathione conjugates.\",\n      \"method\": \"ATP-dependent uptake assay in inside-out membrane vesicles from ABCG2-transfected mouse lymphoma P388 cells; radiolabeled substrate transport with kinetics and inhibitor specificity\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted vesicle transport assay with Km determination and substrate specificity profiling\",\n      \"pmids\": [\"12682043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ABCG2 expressed in Xenopus laevis oocytes mediates efflux of mitoxantrone and flavopiridol (wild-type), and additionally daunorubicin and rhodamine 123 (R482T mutant); mutation of the ATP-binding cassette signature motif serine 187 (S187T or S187A) abolishes transport activity; co-injection of inactive R482T/S187T with active R482T competitively inhibited transport in a dose-dependent manner, consistent with ABCG2 functioning as a homodimer or homomultimer.\",\n      \"method\": \"Xenopus laevis oocyte heterologous expression; efflux/accumulation assays; dominant-negative co-injection experiments; site-directed mutagenesis\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution in oocyte system with active-site mutagenesis and dominant-negative epistasis\",\n      \"pmids\": [\"14645676\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"SNP variants of ABCG2 differentially affect localization and expression: Q141K and S441N variants show significantly lower protein expression levels; S441N mislocalizes to intracellular compartments rather than the apical membrane; transport activity per unit protein is preserved in Q141K, A149P, R163K, Q166E, and P269S variants.\",\n      \"method\": \"cDNA transfection in LLC-PK1 cells for localization; adenovirus-infected HEK293 membrane vesicles for expression and transport activity of estrone-3-sulfate, DHEAS, methotrexate, and PAH\",\n      \"journal\": \"Pharmaceutical research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (localization, expression, and vesicle transport) for multiple SNP variants\",\n      \"pmids\": [\"15553238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ABCG2 (Bcrp1) mediates biliary excretion of pitavastatin: ATP-dependent uptake into BCRP-expressing membrane vesicles (Km ~5.7 µM human, ~4.8 µM mouse), and biliary excretion clearance was reduced 10-fold in Bcrp1-/- mice compared to controls.\",\n      \"method\": \"Membrane vesicle ATP-dependent transport assay; Bcrp1-/- mouse biliary excretion clearance measurement; comparison with MRP2-deficient rats; transcellular transport in MDCKII double transfectants\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — reconstituted vesicle assay plus genetic KO mouse, multiple orthogonal methods\",\n      \"pmids\": [\"15955871\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Bcrp/ABCG2 limits oral bioavailability and restricts distribution of phytoestrogens (daidzein, genistein, coumestrol) to brain, testis, epididymis, and fetus; Bcrp-/- mice showed elevated plasma and tissue levels; Bcrp localizes to the luminal membrane of endothelial cells in blood-testis and blood-brain barriers.\",\n      \"method\": \"Bcrp-/- mouse pharmacokinetics and tissue distribution; MDCKII transcellular transport assay; immunolocalization of Bcrp protein\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO combined with transport assays and direct immunolocalization\",\n      \"pmids\": [\"17644650\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Pheophorbide a (PhA) is a specific substrate for ABCG2 and not P-glycoprotein or MRP1; fumitremorgin C-inhibitable PhA transport correlates with cell-surface ABCG2 expression; tariquidar (1 µM) and UCN-01 (100 µM) inhibit ABCG2-mediated PhA transport.\",\n      \"method\": \"Flow cytometric transport assay in cell lines overexpressing ABCG2, P-gp, or MRP1; comparison with anti-ABCG2 antibody 5D3 surface expression; cytotoxicity assays with inhibitors\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple cell line controls, multiple orthogonal assays, functional inhibitor specificity confirmed\",\n      \"pmids\": [\"14973080\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"FTC (fumitremorgin C) specifically inhibits ABCG2-mediated ATPase activity with half-maximal inhibition at 1 µM; FTC-inhibitable mitoxantrone and prazosin efflux serve as quantitative functional assays for ABCG2, correlating with ABCG2 mRNA levels (r²=0.89 for mitoxantrone).\",\n      \"method\": \"Flow cytometric efflux assay; ATPase activity inhibition assay; Northern blot correlation\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ATPase inhibition assay plus functional efflux assay with strong correlation to expression levels\",\n      \"pmids\": [\"11406094\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Plant-derived cannabinoids (CBN, CBD, THC) inhibit both basal and substrate-stimulated ATPase activity of human ABCG2 and increase intracellular accumulation of ABCG2 substrates (mitoxantrone), resensitizing ABCG2-overexpressing cells to mitoxantrone and topotecan without affecting ABCG2 expression.\",\n      \"method\": \"Flow cytometric substrate accumulation assay; ATPase activity assay; cytotoxicity/chemosensitization assay; immunoblotting for ABCG2 expression\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ATPase assay combined with functional efflux and cytotoxicity, single lab\",\n      \"pmids\": [\"17906686\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Steroid hormones (estradiol, testosterone, progesterone, androstenedione) allosterically inhibit BCRP-mediated estrone sulphate transport in membrane vesicles (non-competitive inhibition); Bcrp localizes to adrenal cortex, adipocyte plasma membranes, and capillaries of endocrine organs in mice.\",\n      \"method\": \"Vesicular transport inhibition assay with Ki determination; immunohistochemistry for Bcrp localization in mouse endocrine organs; qPCR\",\n      \"journal\": \"Cell and tissue research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — kinetic inhibition analysis in vesicles plus direct immunolocalization, single lab\",\n      \"pmids\": [\"22581381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"SIRT1 upregulates ABCG2 expression in the ileum through PGC-1α deacetylation, which then activates PPARγ; siRNA knockdown of PGC-1α or PPARγ blocked SIRT1-induced ABCG2 upregulation, and this pathway suppresses hyperuricemia by enhancing uric acid efflux.\",\n      \"method\": \"Mouse hyperuricemia model; resveratrol treatment; siRNA knockdown of PGC-1α and PPARγ in colon carcinoma cells; ABCG2 protein and mRNA measurement\",\n      \"journal\": \"Endocrine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis by siRNA with in vivo validation, single lab\",\n      \"pmids\": [\"27022940\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The transcription factor E2F1 directly and specifically activates ABCG2 transcription; E2F1 drives chemotherapeutic drug efflux in vitro and in vivo via ABCG2, and ABCG2 inhibition restores E2F1-induced chemotherapy resistance.\",\n      \"method\": \"E2F1 overexpression and knockdown in multiple cell lines; in vivo xenograft models; correlation of E2F1 and ABCG2 in human lung cancers; ABCG2 inhibitor rescue experiments\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple cell systems plus in vivo validation, direct transcriptional activation shown\",\n      \"pmids\": [\"24276245\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ABCG2 knockdown by RNA interference significantly inhibited cancer cell proliferation by reducing S-phase entry, causing G0/G1 arrest associated with downregulation of cyclin D3 and upregulation of p21; chemical inhibition of ABCG2 by fumitremorgin C recapitulated this cell cycle effect.\",\n      \"method\": \"siRNA knockdown; flow cytometric cell cycle analysis; immunoblotting for cyclin D3 and p21; FTC inhibitor treatment in MCF-7/MX and A549 cells\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — RNAi plus pharmacological inhibition with defined mechanistic readouts, single lab\",\n      \"pmids\": [\"19642144\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Kaempferol is a substrate of Bcrp/Abcg2: its intracellular accumulation is increased by the Bcrp inhibitor GF120918, and directional (B-to-A) transport in MDCK/Bcrp1 monolayers is high (transport ratio 63.4) versus control monolayers (ratio 0.68); kaempferol also inhibits Bcrp-mediated quercetin efflux.\",\n      \"method\": \"Transwell transcellular transport assay in MDCK/Bcrp1 cells; intracellular accumulation with specific inhibitors; LC-MS/MS quantification\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — bidirectional transport assay with inhibitor controls, single lab\",\n      \"pmids\": [\"21139040\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"BCRP plays a dominant role in intestinal excretion of genistein sulfate and a significant role in genistein glucuronide excretion; excretion of genistein sulfate was abolished (>90% decrease in small intestine, undetectable in colon) in BCRP knockout mice, while MRP inhibitors had no effect.\",\n      \"method\": \"Rodent intestinal perfusion model in BCRP knockout mice; pharmacological inhibitor comparison; metabolite analysis\",\n      \"journal\": \"The AAPS journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with pharmacological controls, clear functional readout, single lab\",\n      \"pmids\": [\"20582579\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ABCG2 in prostate cells effluxes androgens; inhibition of ABCG2 with Ko143 increases intracellular androgen levels and nuclear androgen receptor (AR) translocation, driving luminal differentiation of prostate stem cells; Ko143-treated xenograft tumors showed more differentiated (CK8+/AR+) cells and reduced ABCG2-expressing cells.\",\n      \"method\": \"ABCG2 inhibitor (Ko143) treatment; nuclear AR quantification; gene expression analysis; mouse xenograft tumor growth assay; immunohistochemistry\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological inhibition with in vitro and in vivo validation, defined mechanistic pathway, single lab\",\n      \"pmids\": [\"27056956\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Hypoxia signaling via HIF-1α downregulates placental BCRP/ABCG2 mRNA and protein expression by 30–75% in BeWo cells, reducing efflux activity (assessed by Hoechst 33342 accumulation); coordinated downregulation of transcription factors AHR, NRF2, and PPARγ was observed; women at high altitude (chronic hypoxia) had reduced BCRP in placental microvillous membranes.\",\n      \"method\": \"HIF-1α activation by CoCl2 and 3% O2 in BeWo cells; qPCR, ELISA, western blotting; fluorescent substrate efflux assay; human placental membrane analysis from high-altitude vs. moderate-altitude pregnancies\",\n      \"journal\": \"Placenta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods in vitro and human tissue validation, single lab\",\n      \"pmids\": [\"28292469\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Pregnancy-related hormones estriol (E3), human placental lactogen (hPL), and human prolactin (hPRL) upregulate BCRP protein and mRNA approximately 2–3-fold in BeWo placental cells; estriol induction is abrogated by the estrogen receptor antagonist ICI-182,780; testosterone together with E2 increases BCRP through E2-mediated upregulation of testosterone receptor.\",\n      \"method\": \"Immunoblotting; quantitative RT-PCR; ER-alpha siRNA knockdown; ER antagonist and AR antagonist pharmacological treatment; confocal immunofluorescence for membrane localization\",\n      \"journal\": \"Pharmaceutical research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple hormones tested, receptor knockdown and antagonist confirmation, single lab\",\n      \"pmids\": [\"17823853\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Post-translational modifications of ABCG2 include disulfide bond formation, ubiquitination, and ER-associated degradation; these modifications regulate ABCG2 protein stability and trafficking.\",\n      \"method\": \"Biochemical characterization reviewed from primary studies (disulfide bond, ubiquitination, ERAD assays)\",\n      \"journal\": \"Xenobiotica\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — review citing primary data without direct experimental detail in abstract\",\n      \"pmids\": [\"18668433\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"BCRP/ABCG2 protein is present in nuclear extracts of glioblastoma cell lines; nuclear BCRP was detected by immunoblotting and confocal microscopy; fumitremorgin C inhibition of BCRP increased mitoxantrone cytotoxicity ~7-fold, further potentiated by siRNA knockdown, suggesting nuclear BCRP may contribute to drug resistance.\",\n      \"method\": \"Subcellular fractionation; immunoblotting; confocal microscopy; siRNA knockdown; cytotoxicity assay with BCRP inhibitor\",\n      \"journal\": \"Xenobiotica\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — nuclear localization identified but functional role of nuclear BCRP not mechanistically resolved\",\n      \"pmids\": [\"22401348\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Regorafenib inhibits ABCG2-mediated drug efflux by stimulating ABCG2 ATPase activity without altering ABCG2 expression or subcellular localization; molecular docking suggests interaction with the transmembrane domain; combination of regorafenib and topotecan showed synergistic effects in ABCG2-overexpressing xenografts.\",\n      \"method\": \"Drug accumulation assay; ATPase activity assay; Western blotting for ABCG2 expression; induced-fit docking and molecular dynamics simulation; in vivo xenograft tumor model\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ATPase functional assay plus in vivo validation; computational docking as supporting evidence; single lab\",\n      \"pmids\": [\"30392788\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ABCG2 is an ATP-hydrolyzing efflux transporter that functions as a homodimer, adopting inward-facing and substrate-bound conformations (resolved by cryo-EM and electron crystallography); it binds chemically diverse substrates—including anticancer drugs, sulfated steroids, porphyrins, and flavonoids—in a central hydrophobic transmembrane pocket, with substrate specificity critically determined by residue 482 and ATPase signature motif serine 187, while its expression is regulated transcriptionally by nuclear receptors (ER, PPARγ via PGC-1α/SIRT1, E2F1) and post-translationally by ubiquitination and ER-associated degradation, enabling its tissue-barrier and pharmacokinetic roles at the placenta, blood-brain barrier, intestine, and liver.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"ABCG2 (BCRP) was identified as a novel 655-amino acid ABC half-transporter overexpressed in multidrug-resistant MCF-7/AdrVp breast cancer cells; enforced BCRP expression conferred resistance to mitoxantrone, doxorubicin, and daunorubicin, reduced daunorubicin accumulation, and caused ATP-dependent enhancement of rhodamine 123 efflux, establishing ABCG2 as a functional xenobiotic efflux transporter.\",\n      \"method\": \"cDNA cloning, transfection/overexpression, drug accumulation/efflux assays, RNA fingerprinting\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — original functional reconstitution with multiple orthogonal assays; foundational discovery paper with >1700 citations\",\n      \"pmids\": [\"9861027\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"ABCG2 (ABCP) was independently cloned as a human placenta-specific ABC transporter; the predicted protein has a single N-terminal ATP-binding domain and a single C-terminal transmembrane domain (half-transporter architecture), closely related to Drosophila white and yeast ADP1, and maps to chromosome 4q22.\",\n      \"method\": \"cDNA cloning, sequence analysis, chromosomal mapping, Northern blot\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original molecular characterization; foundational paper with >670 citations\",\n      \"pmids\": [\"9850061\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"MXR/BCRP/ABCG2 was independently cloned from mitoxantrone-resistant cells and shown to have homology to the Drosophila white gene; overexpression correlated with resistance to topotecan, SN-38, and mitoxantrone, and pharmacodynamic analysis showed that 70% of the intracellular topotecan pool was effluxed within 30 seconds in overexpressing cells.\",\n      \"method\": \"Differential hybridization, Northern blot, drug efflux kinetics, partial revertant correlation\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods across multiple cell lines; replicated across labs\",\n      \"pmids\": [\"10493507\", \"9892175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Amino acid 482 in ABCG2 is a critical determinant of substrate specificity: wild-type arginine at position 482 (R482) transports mitoxantrone but not rhodamine 123 or doxorubicin, whereas acquired mutations R482T or R482G broaden the substrate profile to include rhodamine 123 and anthracyclines, as confirmed by vaccinia virus expression system.\",\n      \"method\": \"Gene sequencing, vaccinia virus expression, drug efflux and cytotoxicity assays, mutagenesis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — site-directed comparison with reconstitution in multiple systems; replicated across labs\",\n      \"pmids\": [\"11559526\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Bcrp1/ABCG2 expression is a conserved molecular determinant of the hematopoietic 'side population' (SP) stem cell phenotype; enforced ABCG2 expression directly conferred the SP phenotype to bone marrow cells and caused reduced maturing progeny both in vitro and in transplantation assays, while Bcrp1 mRNA was sharply downregulated upon differentiation.\",\n      \"method\": \"Retroviral transduction, flow cytometry (Hoechst 33342 exclusion), transplantation assay, RT-PCR\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function and gain-of-function with defined cellular phenotype, in vivo transplantation; >1800 citations\",\n      \"pmids\": [\"11533706\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ABCG2 (MXR) transports mitoxantrone and prazosin (BODIPY-prazosin) but not rhodamine 123 in wild-type-expressing cells; fumitremorgin C (FTC) at 1 µM causes half-maximal inhibition of ABCG2-associated ATPase activity, establishing that ABCG2 is an ATPase whose hydrolytic activity is coupled to substrate transport.\",\n      \"method\": \"Flow cytometry efflux assay, ATPase activity assay, Northern blot\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct ATPase assay combined with functional transport assay\",\n      \"pmids\": [\"11406094\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ABCG2 is expressed in the SP of hematopoietic stem cells and directly mediates Hoechst 33342 efflux; MCF-7 cells retrovirally transduced with ABCG2 showed lower Hoechst 33342 uptake equivalent to drug-selected resistant cells, establishing Hoechst 33342 as an ABCG2 substrate.\",\n      \"method\": \"Retroviral transduction, flow cytometry, Hoechst 33342 transport assay\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function with defined substrate transport phenotype, replicated\",\n      \"pmids\": [\"11801536\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Subcellular localization of BCRP/ABCG2 in normal human tissues was mapped by immunohistochemistry: BCRP localizes prominently to the apical membrane of placental syncytiotrophoblasts, the apical surface of small intestine and colon epithelium, the liver canalicular membrane, and venous/capillary endothelium (but not arterial endothelium); differential glycosylation was observed between drug-selected cell lines.\",\n      \"method\": \"Immunohistochemistry with monoclonal antibodies BXP-21 and BXP-34, immunoprecipitation, Western blot, RT-PCR\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct localization experiment with two independent antibodies across multiple human tissues; >900 citations\",\n      \"pmids\": [\"11309308\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"In Abcg2 knockout mice, Bcrp1 is required to protect against the dietary phototoxin pheophorbide a (a chlorophyll catabolite) and against protoporphyria: knockout mice developed severe phototoxic skin lesions upon light exposure and showed 10-fold elevated erythrocyte protoporphyrin IX; bone marrow transplant from wild-type mice cured the protoporphyria, establishing that erythroid ABCG2 controls porphyrin levels.\",\n      \"method\": \"Knockout mouse model, dietary challenge, bone marrow transplantation, erythrocyte porphyrin measurement\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vivo knockout + rescue with bone marrow transplantation; >600 citations\",\n      \"pmids\": [\"12429862\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The Q141K (C421A) SNP in ABCG2 results in markedly decreased protein expression (similar mRNA but low protein) and low-level drug resistance in transfected cells; in a Japanese population, heterozygous and homozygous carriers express less BCRP protein, indicating reduced efflux capacity.\",\n      \"method\": \"Transfection, Western blot, drug resistance assay, population genotyping\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vitro functional SNP analysis with protein expression measurement, replicated\",\n      \"pmids\": [\"12479221\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Wild-type ABCG2 (Arg482) transports methotrexate (MTX) and its polyglutamate forms (MTX-Glu2, MTX-Glu3) in an ATP-dependent, osmotically sensitive manner as shown by inside-out membrane vesicle transport assays; the mutant Gly482 form does not transport MTX, demonstrating that position 482 also governs MTX transport specificity.\",\n      \"method\": \"Inside-out membrane vesicle transport assay, fumitremorgin C inhibition, competition assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro vesicle reconstitution with mutagenesis comparison\",\n      \"pmids\": [\"14500392\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ABCG2 transports sulfated conjugates of steroids and xenobiotics (estrone 3-sulfate, DHEAS, 4-methylumbelliferone sulfate, E3040 sulfate) in an ATP-dependent manner in membrane vesicles, with Km values of ~13–27 µM; transport is preferentially for sulfate conjugates over glucuronide and glutathione conjugates, suggesting physiological roles in steroid sulfate homeostasis.\",\n      \"method\": \"Inside-out membrane vesicle transport assay with radiolabeled substrates, inhibition studies\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstituted transport assay with multiple substrates and kinetic parameters\",\n      \"pmids\": [\"12682043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Functional BCRP expressed in Xenopus laevis oocytes is a homodimer or homomultimer: mutations in the ATP-binding cassette signature motif (S187T or S187A) abolished transport activity despite high expression, and co-injection of dominant-negative S187T with active R482T suppressed transport in a dose-dependent manner; wild-type transported only mitoxantrone and flavopiridol, while R482T additionally transported daunorubicin and rhodamine 123.\",\n      \"method\": \"Xenopus oocyte heterologous expression, cRNA co-injection dominant-negative analysis, accumulation and efflux assays\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mutagenesis combined with dominant-negative co-injection in reconstituted system\",\n      \"pmids\": [\"14645676\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"BCRP/ABCG2 was localized at the luminal surface of microvessel endothelium in human brain by immunofluorescence confocal microscopy and RT-PCR/Western blot, closely resembling the localization of P-gp, establishing BCRP as a component of the blood-brain barrier.\",\n      \"method\": \"RT-PCR, Western blotting, immunofluorescence confocal microscopy on human brain tissue\",\n      \"journal\": \"Neuroreport\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct protein localization with multiple methods in human tissue; >320 citations\",\n      \"pmids\": [\"12438926\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ABCG2 binds heme and interacts with porphyrins; under hypoxia, Bcrp1(-/-) progenitor cells have reduced colony-forming ability, and this susceptibility is reversed by blocking heme biosynthesis; BCRP expression is transcriptionally upregulated by the HIF-1 hypoxia-inducible factor complex, positioning ABCG2 as a hypoxia-regulated porphyrin efflux transporter in stem cell survival.\",\n      \"method\": \"Knockout mouse progenitor colony assay, heme biosynthesis inhibition, HIF-1 reporter/ChIP-type analysis, binding assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal experiments including genetic rescue, substrate binding, transcriptional regulation; >500 citations\",\n      \"pmids\": [\"15044468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Pheophorbide a (PhA) is an ABCG2-specific substrate; FTC-inhibitable PhA transport in cell lines correlates with ABCG2 surface expression (measured by anti-ABCG2 antibody 5D3), and transport is not observed in cells expressing P-glycoprotein or MRP1 alone, validating PhA as a specific ABCG2 probe.\",\n      \"method\": \"Flow cytometry transport assay, FTC inhibition, antibody 5D3 surface staining correlation\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple cell lines with specific inhibitor control, replicated substrate identification\",\n      \"pmids\": [\"14973080\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"SNP variants of BCRP/ABCG2 affect protein expression and localization: Q141K and S441N variants show significantly lower protein expression than wild type; S441N causes intracellular (non-apical) localization; the transport activity per unit protein (for E1S, DHEAS, MTX) is unchanged for Q141K, indicating the functional deficit is due to reduced protein expression/surface delivery rather than intrinsic catalytic deficiency.\",\n      \"method\": \"Transfection in LLC-PK1 and HEK293 cells, immunofluorescence localization, membrane vesicle transport assays, Western blot\",\n      \"journal\": \"Pharmaceutical research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including localization and quantitative transport per protein expression\",\n      \"pmids\": [\"15553238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"BCRP/ABCG2 mediates biliary excretion of the statin pitavastatin: ATP-dependent uptake was demonstrated in BCRP-expressing membrane vesicles (Km ~5.7 µM for human, ~4.8 µM for mouse), and biliary excretion clearance of pitavastatin in Bcrp1(-/-) mice was reduced to one-tenth of wild type, while MRP2-deficient rats showed no change.\",\n      \"method\": \"Membrane vesicle transport assay, Bcrp1(-/-) mouse in vivo biliary excretion, Eisai hyperbilirubinemic rat comparison, transcellular transport in MDCK double transfectants\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro vesicle reconstitution plus in vivo knockout confirmation\",\n      \"pmids\": [\"15955871\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Bcrp/ABCG2 limits the oral bioavailability and tissue distribution (brain, testis, epididymis, fetus) of phytoestrogens (daidzein, genistein, coumestrol): Bcrp(-/-) mice showed increased plasma levels after oral administration and significantly elevated brain and testis tissue-to-plasma ratios; Bcrp protein was localized to the luminal membrane of endothelial cells in testis and epididymis.\",\n      \"method\": \"Bcrp(-/-) knockout mouse pharmacokinetics, MDCK transfected cell transcellular transport, immunolocalization\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo knockout pharmacokinetics plus in vitro reconstitution and direct localization\",\n      \"pmids\": [\"17644650\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ABCG2 is a urate efflux transporter located in the brush border membrane of kidney proximal tubule cells: functional assays confirmed ATP-dependent urate transport; the Q141K mutation (rs2231142) caused 53% reduction in urate transport rates; population data showed rs2231142 is causal for elevated serum urate and gout, attributing ≥10% of gout cases in whites to this variant.\",\n      \"method\": \"Site-directed mutagenesis, functional urate transport assay, kidney localization, population-based genetic association (14,783 individuals)\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — functional reconstitution with mutagenesis plus large population validation; >500 citations\",\n      \"pmids\": [\"19506252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Common dysfunctional ABCG2 variants (Q141K, Q126X) essentially block gut and renal urate excretion, causing gout: urate transport assays confirmed ABCG2 is a high-capacity urate secretion transporter; 10% of gout patients had genotype combinations resulting in >75% reduction of ABCG2 function (OR 25.8).\",\n      \"method\": \"Urate transport assay, gene sequencing of hyperuricemia patients, quantitative trait locus analysis\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — functional transport assay combined with large clinical cohort; >350 citations\",\n      \"pmids\": [\"20368174\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Structural analysis of purified human BCRP/ABCG2 by 2D electron crystallography at 5 Å resolution revealed an asymmetric ring-shaped transmembrane domain structure; in the absence of mitoxantrone, ABCG2 adopts a more open conformation, while in the presence of mitoxantrone, a more closed/compact conformation is observed, consistent with inward-facing substrate-bound and substrate-free states.\",\n      \"method\": \"Purification from Pichia pastoris, 2D crystallization, cryo-electron microscopy projection maps, homology modeling\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structural determination by electron crystallography with substrate-dependent conformational states\",\n      \"pmids\": [\"20399185\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ABCG2 knockdown (RNAi) in MCF-7/MX and A549 cancer cells significantly inhibited cell proliferation, reduced the S-phase fraction, and caused G0/G1 arrest associated with downregulation of cyclin D3 and upregulation of p21; chemical inhibition by fumitremorgin C produced a similar cell cycle effect, suggesting ABCG2 has a role in cell cycle progression beyond drug transport.\",\n      \"method\": \"RNA interference knockdown, flow cytometry cell cycle analysis, chemical inhibitor FTC, Western blot for cyclins\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — KD with defined phenotypic readout but mechanism only partially characterized\",\n      \"pmids\": [\"19642144\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Steroid hormones allosterically inhibit BCRP/ABCG2-mediated transport: estradiol, testosterone, progesterone, and androstenedione inhibited BCRP-mediated estrone sulfate uptake in membrane vesicles with Ki values of 5–217 µM through non-competitive (allosteric) inhibition; Bcrp is localized in the cortex of the adrenal gland and plasma membranes of adipocytes.\",\n      \"method\": \"Membrane vesicle transport assay with Ki determination, immunohistochemistry, quantitative PCR\",\n      \"journal\": \"Cell and tissue research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro vesicle assay with kinetic analysis, single lab\",\n      \"pmids\": [\"22581381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"E2F1 transcription factor directly activates ABCG2 expression and drives chemotherapeutic drug resistance through ABCG2 in vitro and in vivo; E2F1-induced drug efflux was abrogated by ABCG2 inhibition, and a significant correlation between elevated E2F1 and ABCG2 expression was identified in human lung cancers.\",\n      \"method\": \"E2F1 overexpression and knockdown, luciferase reporter assay (direct promoter activation), in vivo xenograft, gene expression correlation in clinical samples\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct transcriptional regulation established with reporter assay and in vivo confirmation, single lab\",\n      \"pmids\": [\"24276245\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"3D electron crystallography of full-length human ABCG2 without nucleotides or substrates revealed a symmetric homodimer in an inward-facing conformation with widely separated nucleotide-binding domains (NBDs), similar to murine ABCB1, and cytoplasmic extensions connecting TMDs to NBDs were resolved; this was the first 3D structure of full-length ABCG2.\",\n      \"method\": \"2D crystallization, electron crystallography, subtomogram averaging at ~2 nm resolution, homology model refinement\",\n      \"journal\": \"Acta crystallographica Section D\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — first 3D structural determination of full-length ABCG2 confirmed by subtomogram averaging\",\n      \"pmids\": [\"26249353\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ABCG2 mediates androgen efflux in prostate stem cells (PSCs), maintaining an undifferentiated state: Ko143-mediated ABCG2 inhibition increased intracellular androgen levels, leading to nuclear AR translocation, upregulation of AR-regulated genes, and luminal differentiation; in vivo, Ko143 reduced tumor growth and increased percentage of differentiated CK8+/AR+ luminal cells.\",\n      \"method\": \"Ko143 pharmacological inhibition, siRNA knockdown, nuclear AR translocation assay, xenograft mouse model, immunohistochemistry\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological inhibition with defined mechanistic readout in vitro and in vivo, single lab\",\n      \"pmids\": [\"27856956\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"SIRT1 upregulates ABCG2 expression in the ileum through a PGC-1α/PPARγ signaling axis: resveratrol-activated SIRT1 deacetylated PGC-1α, which activated PPARγ to drive ABCG2 transcription; siRNA knockdown of PGC-1α or PPARγ abolished the SIRT1-induced upregulation of ABCG2, reducing serum uric acid in hyperuricemic mice.\",\n      \"method\": \"siRNA knockdown, resveratrol treatment, SIRT1 activation, Western blot, hyperuricemic mouse model\",\n      \"journal\": \"Endocrine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — epistasis established via siRNA in cell lines plus in vivo model, single lab\",\n      \"pmids\": [\"27022940\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"High-resolution cryo-EM structure of human ABCG2 in complex with inhibitory antibody 5D3 Fab fragments was determined: two cholesterol molecules were found bound in the central hydrophobic multidrug-binding pocket within an inward-facing translocation pathway between transmembrane domains; structural data rationalized disease-causing SNPs, explained allosteric inhibition by 5D3 antibody, and revealed a cholesterol recognition mechanism shared with other G-subfamily ABC transporters.\",\n      \"method\": \"Cryo-electron microscopy (high-resolution), complex with 5D3 antibody Fab fragments, functional in vitro transport analyses\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — first high-resolution cryo-EM structure with functional validation; >340 citations\",\n      \"pmids\": [\"28554189\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Placental BCRP/ABCG2 expression is down-regulated by hypoxia: HIF-1α activation (by CoCl2 or 3% O2) reduced BCRP mRNA and protein by 30–75% in BeWo trophoblast cells and impaired substrate efflux activity; women at high altitude (chronic hypoxia) showed reduced BCRP in placental microvillous membranes correlating with elevated HIF-1α target expression.\",\n      \"method\": \"CoCl2 and hypoxia treatment, HIF-1α Western blot/ELISA, qPCR, fluorescent substrate transport assay, human placental tissue analysis\",\n      \"journal\": \"Placenta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro mechanistic data confirmed with human clinical samples, single lab\",\n      \"pmids\": [\"28292469\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Lapatinib directly inhibits ABCG2 transport function: lapatinib stimulated ABCG2 ATPase activity, inhibited photolabeling of ABCG2 with [125I]iodoarylazidoprazosin in a concentration-dependent manner, inhibited ABCG2-mediated methotrexate and E217βG transport, increased mitoxantrone accumulation in ABCG2-overexpressing cells, and enhanced paclitaxel efficacy in ABCB1-overexpressing xenografts, without affecting transporter expression.\",\n      \"method\": \"ATPase stimulation assay, photoaffinity labeling, transport assay, accumulation assay, xenograft in vivo\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple biochemical assays demonstrating direct drug-transporter interaction; >344 citations\",\n      \"pmids\": [\"18829547\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Imatinib mesylate (STI571) is a substrate for BCRP/ABCG2: imatinib competes with mitoxantrone for export in BCRP-overexpressing cell lines, and BCRP-mediated efflux is reversed by the fumitremorgin C analog Ko-143; this suggests BCRP can influence gastrointestinal absorption and cellular resistance to imatinib.\",\n      \"method\": \"Drug competition efflux assay, Ko-143 inhibition, multiple BCRP-overexpressing cell lines\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — substrate identification by competition assay with specific inhibitor, replicated across cell lines; >338 citations\",\n      \"pmids\": [\"15251980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Pregnancy hormones regulate placental BCRP expression: estriol (E3), human placental lactogen (hPL), and prolactin (hPRL) increased BCRP protein and mRNA ~2–3-fold in BeWo cells; the inductive effect of E3 was abrogated by ER antagonist ICI-182,780; testosterone combined with E2 increased BCRP through E2-mediated upregulation of testosterone receptor (TR) mRNA; hCG had no effect.\",\n      \"method\": \"Hormone treatment in BeWo cells, immunoblotting, qRT-PCR, ER antagonist, siRNA knockdown of ERα, immunofluorescence\",\n      \"journal\": \"Pharmaceutical research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — receptor-mediated regulation established with antagonist and siRNA, single lab\",\n      \"pmids\": [\"17823853\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ABCG2 undergoes post-translational modifications including disulfide bond formation, ubiquitination, and ER-associated degradation that regulate its expression and trafficking; these modifications were identified as key determinants of ABCG2 protein stability and surface delivery.\",\n      \"method\": \"Biochemical characterization (disulfide bond analysis, ubiquitination assay, ER degradation experiments)\",\n      \"journal\": \"Xenobiotica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — PTM characterization reported, partially described in review context\",\n      \"pmids\": [\"18668433\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"BCRP/Abcg2 plays a dominant role in intestinal genistein sulfate excretion: in Bcrp knockout mice, genistein sulfate excretion was reduced >90% in small intestine and became undetectable in colon; genistein glucuronide excretion also decreased significantly (78%), demonstrating that BCRP drives apical efflux of sulfated and glucuronidated isoflavone conjugates to prevent backward hydrolysis.\",\n      \"method\": \"Bcrp(-/-) knockout mouse intestinal perfusion model, LC/MS metabolite quantification, inhibitor studies\",\n      \"journal\": \"The AAPS journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo knockout with direct metabolite quantification across two intestinal segments\",\n      \"pmids\": [\"20582579\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ABCG2 (BCRP) is a homodimeric ABC half-transporter that hydrolyzes ATP to drive apical efflux of a broad range of substrates—including anticancer drugs, sulfated steroids, porphyrins, uric acid, and phytoestrogen conjugates—from cells at barrier tissues (intestine, liver canaliculi, placenta, blood-brain barrier, kidney proximal tubule); its substrate specificity is critically determined by residue 482 in the third transmembrane domain, its protein expression and trafficking are modulated by the Q141K SNP (which reduces surface delivery), and its transcription is regulated by HIF-1 under hypoxia, by the SIRT1/PGC-1α/PPARγ axis, and by E2F1, with high-resolution cryo-EM structures revealing an inward-facing homodimer with a central hydrophobic multidrug-binding pocket where cholesterol and substrates bind before ATP-driven translocation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ABCG2 is an ATP-dependent efflux transporter that functions as a homodimer to expel a remarkably broad range of substrates—including anticancer drugs, sulfated steroid conjugates, porphyrins, dietary flavonoids, and statins—across the plasma membrane, thereby governing oral bioavailability, tissue distribution, and biliary/intestinal excretion [PMID:11559526, PMID:12682043, PMID:15955871, PMID:21139040]. Cryo-EM and electron crystallography reveal an inward-facing homodimer whose transmembrane domains form a central hydrophobic pocket that binds cholesterol and undergoes substrate-induced closure upon mitoxantrone binding; residue Arg482 is a critical determinant of substrate selectivity, and mutation of ATP-binding signature-motif Ser187 abolishes transport, while dominant-negative co-expression confirms functional oligomerization [PMID:28554189, PMID:26249353, PMID:20399185, PMID:14645676]. ABCG2 localizes to apical membranes of placental trophoblasts, intestinal epithelium, hepatocytes, and blood–brain/blood–testis barrier endothelium, where it limits fetal, CNS, and systemic exposure to xenobiotics and endogenous metabolites; its expression is upregulated transcriptionally by estrogen receptor signaling and PGC-1α/SIRT1–PPARγ axis and downregulated by hypoxia/HIF-1α, while protein stability is controlled by ubiquitination and ER-associated degradation [PMID:17644650, PMID:17823853, PMID:27022940, PMID:28292469, PMID:18668433]. Beyond drug efflux, ABCG2 influences cell proliferation by modulating cell-cycle progression and contributes to androgen homeostasis in prostate stem cells by effluxing androgens [PMID:19642144, PMID:27056956].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Establishing that ABCG2 is an ATP-dependent efflux pump with residue 482 as a key determinant of substrate selectivity resolved why different drug-resistant cell lines exhibited distinct substrate profiles.\",\n      \"evidence\": \"Sequencing of resistant lines and vaccinia virus expression of wild-type vs. mutant ABCG2 with transport/cytotoxicity assays; ATPase inhibition by FTC correlated with mRNA levels\",\n      \"pmids\": [\"11559526\", \"11406094\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No structural explanation for how residue 482 governs selectivity\",\n        \"Mechanism of ATP hydrolysis coupling to substrate translocation unresolved\"\n      ]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identifying endogenous and conjugated substrates (estrone-3-sulfate, DHEAS, methotrexate) demonstrated that ABCG2 is not solely a drug transporter but handles physiological sulfated conjugates with measurable kinetics.\",\n      \"evidence\": \"ATP-dependent vesicle transport assays with Km determination for sulfated steroids and methotrexate; comparison of wild-type vs. R482G mutant\",\n      \"pmids\": [\"12682043\", \"14500392\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Full endogenous substrate repertoire not catalogued\",\n        \"No structural basis for sulfate-conjugate preference\"\n      ]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstrating that Ser187 in the ATP-binding signature motif is essential for transport and that inactive mutants act as dominant negatives established that ABCG2 functions as a homodimer requiring cooperative ATPase activity.\",\n      \"evidence\": \"Site-directed mutagenesis and co-injection of active/inactive subunits in Xenopus oocyte expression system\",\n      \"pmids\": [\"14645676\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Stoichiometry of higher-order oligomers not excluded\",\n        \"Coupling mechanism between ATP hydrolysis and substrate translocation unknown\"\n      ]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Characterization of pharmacogenomic SNP variants (Q141K, S441N) revealed that reduced expression and mislocalization—rather than intrinsic transport defects—account for functional loss, linking common human polymorphisms to pharmacokinetic variability.\",\n      \"evidence\": \"Transient transfection localization studies in LLC-PK1 cells and vesicle transport assays of multiple SNP variants\",\n      \"pmids\": [\"15553238\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Mechanism of reduced Q141K protein stability not determined\",\n        \"In vivo pharmacokinetic consequences of individual SNPs not fully quantified\"\n      ]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrating that Bcrp/ABCG2 mediates biliary excretion of pitavastatin in knockout mice established a physiological role for ABCG2 in hepatobiliary drug elimination.\",\n      \"evidence\": \"Vesicle transport assay (Km ~5.7 µM) and 10-fold reduction of biliary clearance in Bcrp1-/- mice\",\n      \"pmids\": [\"15955871\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Relative contribution of ABCG2 vs. other hepatic transporters for most statins unknown\",\n        \"Regulatory mechanisms controlling hepatic ABCG2 expression not explored\"\n      ]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Knockout mouse pharmacokinetics showed that ABCG2 limits oral bioavailability and restricts distribution of phytoestrogens to brain, testis, and fetus, establishing ABCG2 as a gatekeeper at multiple tissue barriers.\",\n      \"evidence\": \"Bcrp-/- mouse tissue distribution studies; immunolocalization to luminal endothelial membranes at BBB and blood–testis barrier\",\n      \"pmids\": [\"17644650\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Relative importance at each barrier tissue not quantitatively ranked\",\n        \"Redundancy with P-glycoprotein at these barriers not fully delineated\"\n      ]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Showing that pregnancy hormones (estriol, hPL, hPRL) upregulate ABCG2 through estrogen receptor signaling in placental cells identified a transcriptional regulatory axis that tunes fetal protection during pregnancy.\",\n      \"evidence\": \"ER antagonist and siRNA knockdown abrogating estriol-induced ABCG2 upregulation in BeWo trophoblast cells\",\n      \"pmids\": [\"17823853\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Direct ER binding to ABCG2 promoter not shown\",\n        \"In vivo relevance during human pregnancy not confirmed\"\n      ]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Cryo-EM projection maps of reconstituted ABCG2 revealed substrate-induced conformational closure, providing the first structural visualization of the transport cycle and confirming an inward-facing to occluded transition.\",\n      \"evidence\": \"2D crystallization of purified ABCG2 with cryo-EM projection mapping ± mitoxantrone\",\n      \"pmids\": [\"20399185\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Resolution insufficient for atomic-level mechanism\",\n        \"Outward-facing conformation not captured\"\n      ]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"RNAi and pharmacological inhibition of ABCG2 caused G0/G1 arrest with cyclin D3 downregulation and p21 upregulation, suggesting a role for ABCG2 in cell-cycle progression beyond drug efflux.\",\n      \"evidence\": \"siRNA knockdown and FTC inhibition in MCF-7/MX and A549 cells with cell-cycle analysis\",\n      \"pmids\": [\"19642144\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether cell-cycle effect is substrate-mediated or through direct signaling unknown\",\n        \"Endogenous cell-cycle-relevant substrate not identified\"\n      ]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Electron crystallography of full-length ABCG2 resolved the homodimeric architecture in a symmetric inward-facing conformation with separated NBDs, providing the first three-dimensional model of the substrate-free resting state.\",\n      \"evidence\": \"3D electron crystallography from 2D crystals with subtomogram averaging\",\n      \"pmids\": [\"26249353\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No nucleotide or substrate bound in the structure\",\n        \"Mechanism of NBD dimerization upon ATP binding not resolved\"\n      ]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"SIRT1-mediated deacetylation of PGC-1α activates PPARγ to upregulate intestinal ABCG2, establishing a metabolic sensing pathway that links energy/redox status to uric acid efflux and protection against hyperuricemia.\",\n      \"evidence\": \"Resveratrol-treated hyperuricemia mouse model; siRNA epistasis of PGC-1α and PPARγ in colon carcinoma cells\",\n      \"pmids\": [\"27022940\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Direct PPARγ binding to ABCG2 promoter not demonstrated\",\n        \"Relevance to human gout pharmacogenomics not tested\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"High-resolution cryo-EM of ABCG2 bound to inhibitory antibody 5D3 revealed cholesterol molecules in a central hydrophobic cavity between TMDs, providing the structural basis for multidrug recognition, rationalizing disease SNPs, and showing allosteric inhibition.\",\n      \"evidence\": \"Cryo-EM at near-atomic resolution with functional in vitro analyses\",\n      \"pmids\": [\"28554189\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Substrate-bound transport-competent conformation not captured\",\n        \"Complete outward-facing state still unresolved at high resolution\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"HIF-1α-mediated hypoxia signaling downregulates placental ABCG2 by 30–75%, with coordinated loss of AHR, NRF2, and PPARγ, linking gestational hypoxia to compromised placental barrier function.\",\n      \"evidence\": \"CoCl2 and 3% O2 treatment in BeWo cells; human placental membranes from high-altitude pregnancies\",\n      \"pmids\": [\"28292469\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether HIF-1α acts directly on ABCG2 promoter or indirectly through AHR/NRF2/PPARγ not resolved\",\n        \"Functional consequence for fetal drug exposure not measured\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A complete high-resolution structure of the full transport cycle—including substrate-bound, occluded, and outward-facing states—and identification of the endogenous substrates responsible for ABCG2's cell-cycle and stem-cell effects remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Full conformational cycle at atomic resolution not captured\",\n        \"Endogenous substrate mediating cell-cycle and stemness phenotypes unknown\",\n        \"Relative contributions of transcriptional vs. post-translational regulation in each barrier tissue not quantified\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [0, 2, 5, 6, 8, 11]},\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [3, 4, 5, 6, 8, 9, 10, 17, 18]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [7, 9, 13, 21]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [7, 22]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [3, 4, 5, 6, 8, 9, 10, 17, 18]},\n      {\"term_id\": \"R-HSA-9748784\", \"supporting_discovery_ids\": [8, 9, 18]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [5, 13, 14]}\n    ],\n    \"complexes\": [\n      \"ABCG2 homodimer\"\n    ],\n    \"partners\": [\n      \"5D3 (inhibitory antibody)\",\n      \"PGC-1α\",\n      \"PPARγ\",\n      \"E2F1\",\n      \"ESR1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"ABCG2 (BCRP/MXR) is a homodimeric ABC half-transporter that couples ATP hydrolysis to the apical efflux of a remarkably broad substrate repertoire—including anticancer drugs, porphyrins, sulfated steroid conjugates, uric acid, phytoestrogens, and statins—at pharmacological barrier tissues such as the intestinal epithelium, liver canaliculi, placental syncytiotrophoblast, kidney proximal tubule, and blood–brain barrier endothelium [PMID:9861027, PMID:11309308, PMID:12438926, PMID:19506252]. Substrate specificity is critically governed by residue Arg482 in the third transmembrane segment, where acquired mutations broaden the transported drug spectrum, while the common Q141K polymorphism reduces surface protein levels—without altering intrinsic catalytic activity—leading to impaired urate secretion and clinically significant hyperuricemia and gout [PMID:11559526, PMID:15553238, PMID:20368174]. High-resolution cryo-EM structures reveal an inward-facing homodimer with a central hydrophobic multidrug-binding pocket occupied by cholesterol molecules, rationalizing the polyspecific binding mechanism and allosteric inhibition by antibodies and pharmacological agents [PMID:28554189]. ABCG2 expression is transcriptionally regulated by HIF-1α under hypoxia, the SIRT1–PGC-1α–PPARγ axis, and E2F1, and the transporter defines the hematopoietic side-population stem cell phenotype through Hoechst 33342 and porphyrin efflux, protecting progenitor cells from phototoxic and oxidative damage [PMID:15044468, PMID:11533706, PMID:12429862, PMID:24276245].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"The identification of ABCG2 as a novel half-transporter overexpressed in multidrug-resistant breast cancer cells established it as an ATP-dependent xenobiotic efflux pump, resolving the molecular basis of a mitoxantrone-resistance phenotype that was not attributable to P-gp or MRP1.\",\n      \"evidence\": \"cDNA cloning from MCF-7/AdrVp cells with drug accumulation/efflux assays and independent cloning from placenta\",\n      \"pmids\": [\"9861027\", \"9850061\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural information\", \"Full substrate range unknown\", \"Endogenous physiological substrates not identified\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Mapping of ABCG2 to apical membranes of barrier epithelia (intestine, liver canaliculi, placenta, brain endothelium) and its identification as the molecular determinant of the hematopoietic side-population phenotype established its dual role as a pharmacological gatekeeper and stem cell marker.\",\n      \"evidence\": \"Immunohistochemistry with two independent antibodies across human tissues; retroviral transduction and transplantation assays in bone marrow cells; Hoechst 33342 efflux in transduced MCF-7 cells\",\n      \"pmids\": [\"11309308\", \"11533706\", \"11801536\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking ABCG2 expression to stemness beyond dye efflux unclear\", \"Blood–brain barrier functional significance not quantified in vivo at this stage\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrating that residue 482 governs substrate specificity resolved why different drug-selected cell lines showed discordant resistance profiles and provided the first structure–function insight into the transmembrane drug-binding site.\",\n      \"evidence\": \"Sequencing of resistant lines, site-directed mutagenesis, vaccinia virus expression system with drug efflux and cytotoxicity assays\",\n      \"pmids\": [\"11559526\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No atomic-level explanation for how position 482 alters binding pocket geometry\", \"Only a few substrates tested at this point\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Knockout mice revealed essential physiological roles for ABCG2 in porphyrin homeostasis and protection from dietary phototoxins, demonstrating that ABCG2 is not merely a drug-resistance factor but a guardian against endogenous and dietary toxins.\",\n      \"evidence\": \"Bcrp1−/− mice developed phototoxic lesions and protoporphyria; bone marrow transplant from wild-type donors rescued the phenotype\",\n      \"pmids\": [\"12429862\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full spectrum of endogenous substrates beyond porphyrins not yet defined\", \"Tissue-specific contributions (erythroid vs. hepatic) incompletely resolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Reconstituted vesicle transport assays quantified ATP-dependent transport of methotrexate, sulfated steroids (estrone 3-sulfate, DHEAS), and xenobiotic sulfate conjugates, establishing ABCG2 as a major sulfate conjugate transporter with defined kinetic parameters.\",\n      \"evidence\": \"Inside-out membrane vesicle assays with radiolabeled substrates, Km determination, and position-482 mutagenesis comparison\",\n      \"pmids\": [\"14500392\", \"12682043\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Glucuronide and glutathione conjugate transport appeared minor but was not systematically evaluated\", \"In vivo relevance of steroid sulfate transport not yet demonstrated\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Dominant-negative co-injection experiments in Xenopus oocytes proved that ABCG2 functions as a homodimer (or homomultimer), establishing the minimal functional unit required for transport.\",\n      \"evidence\": \"Co-injection of signature-motif mutant (S187T) cRNA with wild-type cRNA in Xenopus oocytes, dose-dependent suppression of transport\",\n      \"pmids\": [\"14645676\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No direct cross-linking or analytical ultracentrifugation data at this stage\", \"Whether higher-order oligomers exist in native membranes unresolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Characterization of the Q141K polymorphism revealed that its functional deficit arises from reduced protein expression and impaired surface trafficking rather than altered catalytic activity, explaining variable drug pharmacokinetics in carriers.\",\n      \"evidence\": \"Transfection in LLC-PK1 and HEK293 cells with quantitative transport normalized to protein expression, immunofluorescence localization of SNP variants\",\n      \"pmids\": [\"15553238\", \"12479221\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of Q141K-mediated protein instability (ubiquitination, ER retention) not fully elucidated\", \"Population-level pharmacokinetic consequences only partially quantified\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Discovery that HIF-1α transcriptionally upregulates ABCG2 and that ABCG2 binds heme linked the transporter to hypoxia signaling and hematopoietic progenitor survival, explaining why stem cells expressing ABCG2 are protected under low-oxygen conditions.\",\n      \"evidence\": \"Bcrp1−/− progenitor colony assays under hypoxia, heme biosynthesis blockade rescue, HIF-1 reporter analysis\",\n      \"pmids\": [\"15044468\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether HIF-1α acts on ABCG2 promoter directly or indirectly not fully resolved by ChIP at this stage\", \"Relative contribution of porphyrin efflux vs. other substrates to stem cell protection unclear\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identification of ABCG2 as a renal urate efflux transporter, with Q141K causing 53% reduced transport, established a causal link between ABCG2 dysfunction, hyperuricemia, and gout—attributing ≥10% of gout cases in European-descent populations to this variant.\",\n      \"evidence\": \"Functional urate transport assay with site-directed mutagenesis, kidney brush-border localization, population genetic association in 14,783 individuals\",\n      \"pmids\": [\"19506252\", \"20368174\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of intestinal vs. renal ABCG2 to total urate excretion debated\", \"Therapeutic strategies targeting ABCG2-mediated urate transport not developed\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Low-resolution electron crystallography provided the first 3D structural view of ABCG2, revealing an inward-facing homodimer with separated NBDs and substrate-dependent conformational changes, bridging the gap between biochemical data and structural biology.\",\n      \"evidence\": \"2D crystallization and cryo-EM projection maps of purified ABCG2 from Pichia pastoris, with and without mitoxantrone\",\n      \"pmids\": [\"20399185\", \"26249353\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Resolution too low to identify substrate-binding residues\", \"Outward-facing conformation not captured\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"The first high-resolution cryo-EM structure of ABCG2 (with 5D3 Fab) identified two cholesterol molecules in the central multidrug-binding pocket, providing an atomic-level framework for understanding polyspecific substrate recognition, allosteric inhibition, and the structural basis of disease-causing SNPs.\",\n      \"evidence\": \"Cryo-EM of ABCG2–5D3 Fab complex at near-atomic resolution with functional transport validation\",\n      \"pmids\": [\"28554189\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structures with diverse drug substrates bound (e.g., urate, methotrexate) not yet reported in this timeline\", \"Outward-facing ATP-bound state not captured\", \"Mechanism of cholesterol modulation of transport cycle incompletely understood\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the complete conformational cycle of ABCG2 during ATP-driven transport, the structural basis by which residue 482 mutations alter substrate selectivity at atomic resolution, the relative physiological contributions of intestinal versus renal ABCG2 to urate homeostasis, and whether ABCG2's effect on cell cycle progression reflects direct transport of an endogenous signaling substrate.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Full transport cycle intermediates not structurally resolved\", \"Endogenous signaling substrates linking ABCG2 to cell cycle regulation unidentified\", \"Tissue-specific conditional knockouts needed to delineate organ-level contributions\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [0, 5, 10, 11, 19]},\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [0, 2, 10, 11, 17, 19, 34]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [7, 13, 16, 19]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [33]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [0, 2, 10, 11, 17, 19, 20]},\n      {\"term_id\": \"R-HSA-9748784\", \"supporting_discovery_ids\": [17, 30, 31]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [8, 11, 19, 34]}\n    ],\n    \"complexes\": [\n      \"ABCG2 homodimer\"\n    ],\n    \"partners\": [\n      \"HIF1A\",\n      \"PPARG\",\n      \"PPARGC1A\",\n      \"SIRT1\",\n      \"E2F1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}